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 The twin arginine translocation (Tat) pathway of Escherichia coli possesses an 
innate ability to translocate fully folded proteins across the bacterial inner membrane; 
however an in vivo method to directly monitor the protein interactions involved in this 
pathway did not exist.  By using yellow fluorescent protein bimolecular fluorescence 
complementation (YFP-BiFC), protein-protein interactions can now be visualized in 
unprecedented clarity and at near real time rates along the entirety of the Tat pathway.   
 Two interacting proteins previously identified and characterized in the Tat 
pathway, DmsA and DmsD were chosen for YFP-BiFC proof of concept studies.  
Protein fusion chimeras were created, whereby YFP was split into two fragments, Y1 
and Y2, and then attached to the C-terminus of DmsA and DmsD, respectively.  Upon 
coexpression of the two chimeric proteins in vivo, DmsA and DmsD interacted, YFP 
was reconstituted, and upon excitation resulted in the emission of a fluorescent signal. 
 To demonstrate the utility of YFP-BiFC beyond DmsA and DmsD, we made 
protein chimeras targeting every part of the Tat pathway.  With these chimeras, we 
were able to detect a fluorescent signal for interactions between substrate-chaperone, 
substrate-machinery, chaperone-machinery, and machinery-machinery interactions.  
From these interactions, a quantitative fluorescent signal was obtained, showing a 
dynamic range in signal intensity depending on the type of interaction being 
 monitored.  Additionally, in vivo localization of the protein chimeras could be 
determined by fluorescence microscopy.   
 Furthermore, we expanded the applicability of YFP-BiFC in four ways; 1) we 
generated a DmsD library to isolate higher affinity DmsA binding variants by 
screening for an increase in YFP-BiFC signal, 2) we used the irreversible association 
of YFP-BiFC to purify the DmsA and DmsD complex for crystallography studies, 3) 
we used a family of de novo designed 3-helix bundle proteins to investigate the ability 
of the Tat pathway to interact with proteins of varying degrees of stability, and 4) we 
were able to obtain a FRET signal between the DmsA-DmsD YFP-BiFC complex and 
TatC-CFP. 
 Overall, YFP-BiFC is a powerful tool for monitoring protein interactions in 
vivo and as a stabilizing force for in vitro protein analyses.  
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PREFACE 
 
 This Ph.D. dissertation has been written as two parts, whereby the first part 
(Chapter 1) demonstrates in fine detail the in vivo ability of YFP-BiFC to detect a 
variety of protein-protein interactions (e.g. cytoplasmic, transmembrane, and 
cytoplasmic-transmembrane) throughout the E. coli Tat-pathway. The second part 
(Chapters 2 – 5), demonstrates how YFP-BiFC can be expanded and applied to library 
screens, in protein purification and crystallography studies, in understanding how de 
novo designed proteins interact with Tat components, and how multiple protein-
protein interactions can be detected through a combined YFP-BiFC-FRET analysis. 
 It is the author’s intent that readers gain an understanding of the methodology 
of YFP-BiFC, view examples of how and where YFP-BiFC has been applied towards 
the understanding of protein-protein interactions in the Tat pathway of E. coli, and 
subsequently utilize this dissertation as a catalyst to develop novel applications of this 
technique to further elucidate scientific inquiries.  
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CHAPTER 1 
 
THE TWIN ARGININE TRANSLOCATION (TAT) PATHWAY –  
MONITORING PROTEIN INTERACTIONS VIA YFP-BiFC 
 
1.1 Introduction 
 The Twin Arginine Translocation (Tat) pathway was initially discovered in 
1991 by researchers studying protein export in chloroplasts (7,8).  Tat directed protein 
secretion is unlike the well studied general secretory (Sec) export pathway (9-12); 
notably for the ability of Tat to export fully folded proteins across energy transducing 
membranes (13).  Furthermore unlike Sec, Tat transport has three distinct 
characteristics: 1) the energy required to move proteins across membranes is derived 
from the proton motive force (pmf) existing across charged membranes, and not from 
the hydrolysis of adenosine triphosphate (ATP) as in the Sec pathway (14,15)) the 
signal peptide that targets the proteins to the Tat pathway is longer than signal 
peptides in Sec, has a predicted alpha-helical secondary structure (16), and contains 
two highly conserved arginine residues; 3) the Tat pathway is not a universally 
conserved protein export pathway (17,18) but to date has been identified in archaea, 
bacteria (both Gram-positive and negative), chloroplasts, and plant mitochondria (19).   
 Finally, the Tat pathway does not demonstrate any homologous translocation 
machinery components in eukaryotic organisms.  Elimination of Tat pathway 
components results in the attenuation of virulence in numerous bacterial pathogens 
(20-24).  From these results, the development of Tat-pathway specific bactericidal or 
bacteriostatic drugs has been postulated (25), however one of the major limiting 
factors in the development of these therapeutics is the creation of facile dynamic 
reporter assays that can monitor protein interactions through the Tat pathway.  A proof 
 2 
of concept reporter assay that confers antibiotic resistance via protein fragment 
complementation when the Tat pathway is functional has been demonstrated in 
Mycobacterium tuberculosis in an academic setting (26), however converting this 
assay for industrial scale-high throughput drug screens has yet to be attempted (27).       
 Here we present a fluorescent reporter with a wide dynamic range that can be 
used in vivo to monitor the protein interactions across the entirety of the E. coli Tat 
pathway and which has the potential for high throughput analysis.   
    
1.2 The E. coli Twin Arginine Translocation (Tat) Pathway  
 The E. coli Tat pathway consists of two distinct protein components that 
function synergistically with one another and allow for the export of proteins (also 
known as substrates) across the bacterial inner membrane.  The first protein 
component, the Tat translocation complex, consists of three integral membrane 
proteins TatA, TatB, and TatC (Figure 1.1 A).  In E. coli TatA and TatB are single-
span transmembrane proteins that share a similar structure and sequence, however 
TatB has evolved and diverged in sequence from TatA (18), while TatC contains six 
transmembrane spans (28).  Additionally in E. coli TatA has been duplicated to give 
rise to TatE, however TatE is expressed at a low level and deletion of this protein does 
not affect export of Tat substrates into the periplasm (29).   If any of the proteins in 
translocation complex are deleted (with the exception of TatE), export of Tat-specific 
proteins will be inhibited, the proteins will accumulate in the cytoplasm, and the cell 
phenotype will switch from single rod-like shaped cells to elongated filamentous 
chains due to the cell wall amidase lpxC that is not exported into the periplasm by the 
Tat pathway (30).  Truncation analysis (31), site-directed mutations (32-39), and 
domain-swapping (31) of the translocation complex proteins have been evaluated and 
have allowed for a better understanding of how the translocon functions and how Tat  
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substrates interact with the translocon and are subsequently transported into the 
periplasm.    
Figure 1.1 Graphical depiction of the Tat Pathway machinery components and 
timeline of export through the Tat pathway.  (A) The three transmembrane 
components that make up the Tat Pathway.  (B) DNA is transcribed to mRNA and is 
bound by a ribosome that initiates synthesis of a protein, exposing the signal peptide.  
The signal peptide is bound by a Tat-chaperone and inhibited from Sec export (a).  
After protein release from the ribosome, tertiary protein structure is attained in the 
cytoplasm and cofactors are incorporated (b). The protein-chaperone complex is 
directed to the TatBC complex (c), the chaperone is released, TatA is recruited (e), 
creating the TatABC translocon.  The protein is exported into the periplasm, the signal 
peptide is cleaved (f), resulting in a mature protein.  Adapted from Lee et. al. 2006 (5).   
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 These membrane proteins have been observed to form two distinct complexes 
(Figure 1.1 B):  one that is comprised of multiple subunits of TatA and a second that 
contains predominantly TatB and TatC proteins (40-42).  TatA homo-oligomers have 
been observed to form a variable diameter ring structure that may serve as a protein-
conducting channel (43) or a patch that facilitates translocation by local destabilization 
of the bilayer (44).  TatB when expressed in E. coli strains without other Tat 
machinery components can self associate and form homo-oligomeric complexes 
(5,45), however when TatC is present this homo-oligomeric complex is disrupted, in 
favor of the heteromeric associated TatB-TatC proteins that form a complex to which 
substrates initially bind (46), suggesting that TatBC serves as the twin-arginine signal 
peptide binding site.   
 The Tat-pathway proteins and their associated chaperones, make up the second  
protein component of the Tat pathway.  Proteins destined for the Tat pathway (Figure 
1.1 B) are transcribed from DNA into mRNA, and then translated by a ribosome into a 
polypeptide which carries an N-terminal signal peptide sequence.  This signal peptide 
consists of a tripartite structure: a) a positively charged N-terminal region of variable 
length, b) a 15-20 amino acid hydrophobic region, and c) a polar C-terminal region 
containing a peptidase motif for cleavage of the signal peptide upon export (16).  
Within the N-terminal region of the signal peptide, the Tat-consensus motif is defined 
by the amino acid sequence S-R-R-x-F-L-K, where the characteristic and invariant 
twin-arginine residues precede a variant amino acid (x) and the hydrophobic region.   
   Cytosolic chaperones, such as DmsD and TorD (47-51) will bind to the signal 
peptide, prevent targeting to the Sec pathway, protect the protein from premature 
signal peptide cleavage by peptidases, and assist the protein during its folding in the 
cytoplasm.  Proteins targeted to the Tat pathway typically fold rapidly, attain their 
tertiary structure, associate and bind protein subunits (52,53) and/or redox cofactors 
 5 
(54), such as FeS clusters or molybdopterin centers resulting in a Sec-incompatible  
protein within the cytoplasm (55).   
 After the substrate has matured (by binding to a chaperone and/or a cofactor), 
it is targeted to the TatBC complex at which point the signal peptide is released by the 
chaperone and “handed” over to TatC (39).  Once the substrate-TatBC complex is 
formed, TatA is recruited, and through a yet unconfirmed step, the substrate is 
transported into the periplasm.  Within the periplasm, the signal peptide is now 
exposed, revealing a signal peptidase-I recognition sequence which can be 
proteolytically cleaved (56) yielding the mature protein.       
 To understand the E. coli Tat pathway and the protein-protein interactions 
which occur within it, numerous experiments have been preformed both in vivo and in 
vitro, however not all results provide the clarity necessary to understand the dynamic 
interactions within the pathway.  Therefore, we explored if bimolecular fluorescence 
complementation (BiFC) could be adapted for visualizing protein-protein interactions 
in vivo throughout the entirety of the E. coli Tat pathway.    
 
1.3 Yellow Fluorescent Protein - Bimolecular Fluorescence Complementation 
(YFP-BiFC)  
 Many Tat pathway protein-protein interactions described previously were 
identified using traditional protein purification and identification methods (e.g. 
column chromatography (57), bacterial two-hybrid systems (1)).  These techniques are 
either done in vitro or depend on a secondary reporter (e.g. fluorescent, enzymatic) to 
relay a signal that the protein interactions under interrogation occurred.  YFP-BiFC 
eliminates the limitations of these techniques by detecting the protein interactions in 
vivo as well as providing a direct measure of the interaction through the emission of a 
fluorescent signal. 
 6 
 Numerous fluorescence-based methods have been developed for visualizing 
and identifying interacting proteins including FRET (58,59) and BiFC (60,61).  In the 
case of YFP-BiFC (Figure 1.2 A), yellow fluorescent protein is split at a loop between 
two beta sheets, generating two non-fluorescent fragments, Y1 (aa 1-157) and Y2 (aa 
157-238).  When these two fragments are fused to a pair of interacting proteins (Figure 
1.2 C), the native affinity between the proteins brings the split fragments into close 
proximity, resulting in the reassembly of the fluorescent protein.  In this manner, the 
reconstituted fluorescence is directly coupled to the interaction between the two 
proteins and can be used to determine when and where in vivo the two proteins 
interact.  Nyfeler et. al. 2005 (62) first demonstrated the YFP-BiFC technique in 
mammalian cells and we have applied this technique to monitor various protein 
interactions throughout the E. coli Tat pathway using a two-plasmid approach (Figure 
1.2 B). 
 The YFP fragments, Y1 and Y2 were cloned into two plasmid vectors named 
p_POI_-Y1 and p_POI_-Y2, where proteins of interest (POI) could be cloned N-
terminally in frame to the respective fragments.  Coexpression of these plasmids in 
cells is possible due to their antibiotic resistance markers (ampicillin and kanamycin 
resistance, respectively), while plasmid copy number levels are regulated based on 
origins of replication (pBR322 and p15A, respectively), and protein expression is 
induced with the addition of a isopropyl β-D-1-thiogalactopyranoside (IPTG) in a 
titratable manner.  Additionally a flexible linker, consisting of amino acids RSIAT or 
KQKVMNH for Y1 or Y2, respectively (60) was inserted between the POI and the 
YFP fragments to allow for a degree of flexibility between the fusion proteins.  In all 
the experiments described hereafter, only the POI was altered; therefore changes in 
fluorescent signal intensity detected by YFP-BiFC are solely dependent on the two 
interacting proteins.   
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 The benefits of using YFP-BiFC over other protein fragment complementation 
Figure 1.2 YFP-BiFC.  (A) YFP is split between amino acids 157 and 158 to generate 
two fragments, Y1 and Y2, which are used for YFP-BiFC (PDB ID 1yfp).  (B) The 
two plasmid system used to co-express fusions between proteins of interest (POI) and 
the Y1 or Y2 fragments.  (C) Coexpression of protein A-Y1 with D-Y2 results in the 
refolding of the two YFP fragments, chromophore cyclization and fluorescence of 
YFP.  
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assays (PCA) stems from: a) fluorescence is easily detected, it can be quantified, and 
fluorescent proteins have been well characterized by the scientific community; b) no 
cell permeable substrates (e.g. ampicillin for beta-lactamase) for enzymatic reporters 
need to be supplemented to the system to generate a detectable signal and c) fusion 
proteins will continue to interact with other cellular proteins without altering their 
native interactions  (61,63-65).   
 However, there are caveats against using YFP-BiFC as a sole reporter for the 
detection of protein interactions.  The first limitation of the assay lies in the 
irreversible association between the fluorescent fragments (60,62,66,67), which can 
inhibit native interactions between the proteins of interest if disassociation of one of 
the proteins is required for further downstream reactions.  Since the YFP-BiFC assay 
is dependent on protein folding and subsequent fluorophore ring cyclization, the 
protein-protein interactions cannot be studied at real time rates (e.g. on the order of 
seconds or minutes), rather an hour needs to elapse before a detectable signal arises 
(68).  Another limitation of this assay is the ability of the Y1 fragment to cause the 
fusion protein to destabilize and subsequently cause the protein chimera to be 
proteolytically degraded or is packaged into insoluble inclusion bodies (66,67).  To 
overcome this destabilization effect of the Y1 fragment, fusion proteins to Y1 are 
expressed on a high copy vector allowing for a sufficient amount of protein to be 
expressed to allow for the proteins of interest to associate and subsequently generate a 
YFP-BiFC signal (60,66,69).  Another limitation to the YFP-BiFC assay is the 
strength of affinity between the two interacting proteins.  The affinity limit in terms of 
the disassociation constant (KD) to generate a detectable YFP-BiFC signal was ~1mM 
when an interacting leucine zipper library was screened (70).  The final limitation of 
this assay is the steric hindrances imposed by proteins to which the fragments are 
fused which prevents the fragments from interacting and subsequently folding to  
 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generate the fully folded YFP protein.  To overcome this limitation, the directed 
design of linkers can be undertaken, but it is favorable to minimize external variables 
like various types of linkers and maintain a constant linker length between different 
Figure 1.3 Types of protein-protein interactions detected via YFP-BiFC in the E. 
coli Tat Pathway.  (A) Two soluble protein interactions in the cytoplasm, (B)  
homomeric transmembrane protein interactions, (C) heteromeric transmembrane 
protein interactions, (D) soluble cytosolic protein interacting with a transmembrane 
protein.  
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protein chimeras.  Additionally extended linker lengths can promote proteolytic 
degradation and loss of the YFP fragments from their fusion partners. 
 The protein interactions that we wished to visualize with YFP-BiFC (Figure 
1.3) in vivo in the E. coli Tat pathway are: (A) two heterologous soluble cytoplasmic 
proteins, (B) two homologous inner membrane anchored proteins, (C) two 
heterologous inner membrane proteins, and (D) a soluble cytoplasmic protein 
interacting with an inner membrane anchored protein.  To demonstrate the  
applicability of YFP-BiFC in the E. coli Tat pathway, the first set of protein-protein 
interactions targeted was the interaction between two heterologous soluble 
cytoplasmic proteins, E. coli DmsA and its cognate binding chaperone DmsD.        
1.4 Detection of substrate-chaperone interactions 
 The E. coli protein DmsA (a dimethyl sulfoxide reductase) and its cognate 
chaperone DmsD (49,57,71,72),  are well characterized native Tat pathway proteins.  
The DmsD chaperone recognizes the DmsA twin-arginine signal peptide (57) and 
assists in the biogenesis and assembly of the DmsA enzyme (73).  Binding of DmsD 
to the signal peptide provides specific advantages to DmsA: a) protection from 
premature cleavage of the Tat-signal peptide (50), b) DmsD assists in the maturation 
of DmsA by allowing molybdenum cofactor insertion, and c) the interaction serves as 
a proofreading step that prevents premature export of incompletely folded DmsA 
(74,75).   
1.4.1 DmsA and DmsD interactions monitored with YFP-BiFC 
 Since the DmsA signal peptide (ssDmsA) alone is sufficient to interact with 
DmsD (57), we created protein chimeras whereby ssDmsA was fused to the Y1 
fragment (ssDmsA-Y1), while DmsD was fused to the Y2 fragment (DmsD-Y2).  
Upon coexpression of the two constructs in wt TG1 E. coli cells, a strong YFP-BiFC 
signal was detectable with fluorescence microscopy (Figure 1.4 A, left panel) and with  
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Figure 1.4 Proof of concept of YFP-BiFC between ssDmsA and DmsD.  (A) 
Fluorescence microscopy images of ssDmsA-Y1/DmsD-Y2 coexpressed in either wt 
TG1 or TG1 ∆tatC cells (left panel, middle panel, respectively), and TG1 wt cells 
expressing ssPhoA-Y1/DmsD-Y2 (right panel) as a negative control.  (B) FACS 
analysis of cells expressing indicated plasmid combinations from the average of 6 
replicate experiments (n = 6).  (C) Western blot analysis of periplasmic (per) or 
cytoplasmic (cyt) fractions from wt TG1 or TG1 ∆tatC expressing ssDmsA-
Y1/DmsD-Y2 or ssPhoA-Y1/DmsD-Y2. Y1 was detected by antibodies against a C-
terminal FLAG epitope tag, Y2 was detected using an anti-GFP, and GroEL was used 
as a fractionation marker and was detected using anti-GroEL. 
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fluorescence activated cell sorting (FACS) (Figure 1.4B) where the two interacting 
proteins generated a fluorescent signal 5 times brighter than the background control 
cells which were expressing an unfused version of Y1 and DmsD-Y2.  The low levels 
of background fluorescence observed were likely due to self-assembly of the YFP 
fragments in the cytoplasm.  When both ssDmsA-Y1/DmsD-Y2 were coexpressed in a 
Tat-pathway transport defective strain, TG1 ∆tatC, and equally strong fluorescent 
signal was observed (Figure 1.4 A and B) indicating the interaction between the two 
proteins was not dependent on a functional Tat-pathway.  Importantly, when ssDmsA 
was replaced with a Sec-directed signal peptide, ssPhoA, and then coexpressed with 
DmsD-Y2 in wt TG1 cells, no fluorescent signal above the background negative 
control Y1/DmsD-Y2 (Figure 1.4 A and B) was detected.  This result validates the  
YFP-BiFC signal observed was highly specific for the ssDmsA-Y1/DmsD-Y2 
interaction and protein exclusivity between the Sec and Tat protein export pathways. 
 To determine if the chimeric protein ssDmsA-Y1 was still recognized and 
exported into the periplasm by the Tat translocase, we determined the subcellular 
localization of ssDmsA-Y1 when coexpressed with DmsD-Y2 in either wt or ∆tatC 
TG1 cells by Western blot analysis.  As expected, ssDmsA-Y1 localized in the 
periplasm of wt TG1 cells, but was retained in the cytoplasmic fraction for ∆tatC TG1 
cells (Figure 1.4 C – first column, top row).  As for coexpression of ssPhoA-Y1 with 
DmsD-Y2, the protein chimera is detected in the periplasmic fraction, indicating 
export via Sec (Figure 1.4 C – second column, top row) and also in the cytoplasm 
demonstrating an overwhelmed Sec translocon.  This result indicates that the lack of 
an observable YFP-BiFC signal for the coexpression of ssPhoA-Y1/DmsD-Y2 is not 
due to poor expression, or the highly efficient Sec translocon, rather it is due to lack of 
crosstalk between the Sec substrate and Tat chaperone.        
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1.4.2 DmsA and DmsD interactions monitored with RFP-BiFC 
 We next sought to determine if a non-engineered spectral variant of green 
fluorescent protein (GFP), specifically DsRED could be used for RFP-BiFC analysis 
within the E. coli Tat pathway.  The rapidly maturing red fluorescent protein, DsRED, 
was initially isolated from the Discosoma sp. and through subsequent evolution a 
monomeric variant, mRFP1 Q66T, was isolated (76) with increased brightness and 
photostability.  By examining the crystal structure of the protein (77) and comparing 
published RFP-BiFC split sites (76), we made two RFP fragments, termed R1 (aa 1-
154) and R2 (aa 155-225) and replaced the Y1 and Y2 fragments in ssDmsA-Y1 and 
DmsD-Y2, respectively.  Upon coexpression of ssDmsA-R1/DmsD-R2 in wt TG1 
cells (Figure 1.5) we obtained nearly identical BiFC results as we had seen in the 
YFP-BiFC case.  This result suggests that the signal detected via YFP-BiFC was due 
to the specificity and affinity between the substrate/chaperone interaction and not an 
artifact of the split reporter proteins.  
1.4.3 DmsD-Y2-SsrA – a reporter for hitchhiker translocation 
 An open question was whether the ssDmsA-Y1 that was observed in the 
periplasm (Figure 1.4 C) was exported alone or was co-localized in a non-
physiological complex with DmsD-Y2.  This co-localization was a possibility because 
a) YFP-BiFC is an irreversible association, trapping the interacting proteins in a stable 
complex (66) and b) co-localization of partner proteins – termed hitchhiker 
translocation – has been observed for native and engineered Tat substrates (53,78).  
However, two lines of evidence demonstrate against co-localization of the substrate 
with the chaperone in the periplasm.  The first piece of evidence, as seen in our 
fractionation data (Figure 1.4 C, second row), the DmsD-Y2 chimera was localized 
strictly in the cytoplasmic fraction.  To further corroborate this fractionation data, we 
created a DmsD-Y2-SsrA chimera, where the SsrA tag targets the protein for 
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Figure 1.5 RFP-BiFC reports on ssDmsA DmsD interactions.  (A) The fluorescent 
protein, mRFP1Q66T, was spilt into two fragments R1 (residues 1-154) and R2 
(residues 155-238).  Fluorescence microscopy images showing coexpression of 
ssDmsA-R1 with DmsD-R2 resulting in RFP BiFC (right bottom panel) with controls 
coexpressing the unfused R1 and/or R2 fragments as indicated.  (B) Quantification of 
RFP BiFC signals using a microplate reader with fluorescence signal normalized to 
ssDmsA-R1/DmsD-R2 from the average of 3 replicate measurements (n = 3).    
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proteolytic degradation if present in the cytoplasm (79,80).  If the coexpression of 
ssDmsA-Y1/DmsD-Y2-SsrA results in a Tat transport incompetent complex, a 
fluorescent signal would not be observed, however if the complex can be transported 
via Tat, a fluorescent signal should be observed that localizes to the periplasm. 
 Upon coexpression of either ssDmsA-Y1 or the full-length version of DmsA 
(DmsA-Y1) with DmsD-Y2-SsrA, no YFP-BiFC signal was observable under FACS 
analysis (Figure 1.6).  As a positive control, the plasmid pssTorA-GFP-SsrA (81) 
demonstrated that a fluorescent signal can be obtained from the periplasmically 
localized GFP which was exported by the Tat pathway and avoided cytoplasmic 
degradation.  The results from the Western blot and the DmsD-Y2-SsrA reporter 
protein demonstrate that hitchhiker translocation is disallowed when one of the 
subunits is a proofreading chaperone.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 YFP-BiFC constructs localize in the cytoplasm.  DmsD-Y2 with or 
without a C-terminal SsrA tag (+SsrA and –SsrA, respectively) was coexpressed with 
the negative control Y1(-), ssDmsA-Y1, or DmsA-Y1.  Median fluorescence values 
obtained from FACS analysis with 3 replicate measurements (n = 3) and the data was 
normalized to the ssDmsA-Y1/DmsD-Y2 signal.  The sstorA-GFP-SsrA plasmid was 
used as a positive control for the Tat-mediated rescue of SsrA-tagged GFP by export 
into the periplasm.  
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1.4.4 DmsA and DmsD YFP-BiFC occurs in the absence of TatABCE proteins  
 General cellular chaperones and specific Tat pathway proofreading chaperones 
typically bind to their substrates at an early stage of polypeptide synthesis.  
Specifically in the Tat pathway, this binding event is uncoupled from the membrane 
translocation step (75).  As demonstrated previously (Figure 1.4), coexpression of 
ssDmsA-Y1 with DmsD-Y2 in a ∆tatC TG1 strain resulted in a fluorescent YFP-BiFC 
signal.  We next wished to determine if the substrate-chaperone interactions required 
any specific part of the TatABCE proteins that make up the Tat-translocon or if this 
interaction was independent of these components.   
 Coexpression of ssDmsA-Y1/DmsD-Y2 in various tat-deficient TG1 strain 
backgrounds resulted in a significant YFP-BiFC signal increase even when the Tat 
pathway was partially (∆tatE) or completely (∆tatAE, ∆tatB, ∆tatC, and ∆tatABCE) 
inactivated in TG1 cells (Figure 1.7 A).  We additionally constructed a full length 
DmsA chimera (DmsA-Y1) to determine if YFP-BiFC could be used to interrogate 
full length Tat substrates with their corresponding chaperone.  Coexpression of 
DmsA-Y1/DmsD-Y2 resulted in an YFP-BiFC signal that was over background, but 
which was 50% the intensity of the ssDmsA-Y1/DmsD-Y2 interaction (Figure 1.7 B).  
The decrease in signal intensity is likely the result of steric hindrance caused by the 
larger DmsA-Y1 construct (110kDa versus 24kDa for ssDmsA-Y1, respectively) and 
the ability of DmsD to interact with other regions of full length DmsA (82). 
It is noteworthy that coexpression of ssDmsA-Y1 or DmsA-Y1 with DmsD-Y2 in tat-
deficient strains (∆tatAE, ∆tatB, ∆tatC, and ∆tatABCE) resulted in a greater YFP-
BiFC signal when compared to wt TG1 or ∆tatE TG1 cells.  We believe this increase 
in fluorescence is due to the retention of ssDmsA-Y1 or DmsA-Y1 cytoplasmically, 
making all of the substrate available for YFP-BiFC complementation with DmsD-Y2, 
while in the wt TG1 or ∆tatE TG1 cells a portion of the substrate is exported into the  
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periplasm (Figure 1.4 C) since TatE is not an essential Tat pathway protein and TatA 
can substitute for the lack of TatE. 
1.4.5 Twin-lysine mutations to DmsA 
 We next applied YFP-BiFC to determine if a functional Tat signal peptide was 
necessary to obtain a fluorescent signal.  The twin-arginine residues in the Tat signal 
peptide consensus motif, S-R-R-x-F-L-K, were mutated to lysine residues (S-K-K-x-
F-L-K), a substitution that completely abolishes export of Tat proteins (80,83).  This 
same substitution, when applied to a truncated form of the ssTorA signal peptide in 
Figure 1.7 YFP-BiFC of DmsA and DmsD interacting in various Tat-deficient 
cells.  (A) Coexpression of ssDmsA-Y1/DmsD-Y2 or (B) DmsA-Y1/DmsD-Y2 in 
various TG1 Tat deletion strains as indicated.  Mean fluorescence was obtained via 
FACS and normalized to that for the wt TG1 ssDmsA-Y1/DmsD-Y2 interaction.  Data 
is from the average of 6 replicate experiments (n = 6).    
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vitro, had no effect on the binding affinity for the proofreading chaperone TorD when 
measured by isothermal titration calorimetry (ITC) (48).   
 We made the twin lysine mutations to both ssDmsA-Y1 and DmsA-Y1 
generating ssDmsA(KK)-Y1 and DmsA(KK)-Y2 and coexpressed these constructs 
with DmsD-Y2 in wt TG1 cells.  A strong YFP-BiFC signal was observed, however 
our in vivo analysis (Figure 1.8 A) demonstrated a 20-30% decrease in the 
fluorescence signal intensity between the twin-lysine when compared to the twin-
arginine counterparts.  This decrease in signal intensity between the twin-arginine and 
twin-lysine signal peptides can be attributed to the experimental conditions (in vivo 
versus in vitro) of this assay, to the utilization of the full length DmsA signal peptide 
or full length DmsA protein fused to Y1 and not a truncated variant of a Tat substrate 
(e.g. ITC experiments with ssTorA) and the affinity of the chaperone to the substrate 
which in turn affects the fluorescence intensity of the YFP-BiFC.  Our results are 
consistent with the observations that the binding activity of proofreading chaperones is 
uncoupled from the membrane translocation step and the type of amino acid that is 
present in the canonical twin arginine motif of the signal peptide.                 
1.4.6 DnaK and crosstalk between Tat pathway chaperones and substrates 
 Other general molecular chaperones such as DnaK have been observed to 
interact with Tat substrates (57,84,85), presumably at an early stage of polypeptide 
synthesis and may participate in some form of protein proofreading.  Coexpression of 
DnaK-Y2 with either ssDmsA-Y1 or DmsA-Y1 (Figure 1.8 A) resulted in a detectable 
YFP-BiFC signal in wt TG1 cells, however this fluorescent signal was much lower 
than that observed for the DmsD-Y2 interaction.  Such a weak YFP-BiFC signal can 
be attributed to two potential factors, a) a less specific and/or a lower affinity of DnaK 
for DmsA compared to DmsD and b) tertiary structure differences (69kDa size of 
DnaK compared to 24kDa size of DmsD) that cause steric hindrances between the 
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YFP fragments inhibiting YFP-BiFC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Interactions between various Tat pathway substrates and chaperones.  
(A) Coexpression of DmsD-Y2 with wt ssDmsA-Y1, full length DmsA or twin-lysine 
(KK) variants of ssDmsA-Y1 or DmsA-Y1 in a wt TG1 background.  DnaK-Y2 was 
also co-expressed with ssDmsA-Y1 or DmsAY1.  Y1 coexpressed with DmsD-Y2 or 
DnaK-Y2 served as negative controls.  (B) Chaperones DmsD, TorD and NarJ fused 
to Y2 were coexpressed with their cognate or non-cognate signal sequences fused to 
Y1 (ssDmsA, ssTorA, ssNarG).  Median cell fluorescence obtained via FACS a 
averaged from 6 replicate experiments (n = 6) and all data was normalized to the wt 
TG1 cells coexpressing ssDmsA-Y1/DmsD-Y2.  
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 In addition to the aforementioned interacting protein pair DmsA/DmsD, 
additional substrate/chaperone pairs have been identified in the Tat pathway; these 
include TorA/TorD and NarG/NarJ.  As with DmsD, TorD and NarJ have been 
experimentally shown to bind the signal peptide region of their respective substrates 
(TorA and NarG, respectively) (86-88).  Although these chaperones have specificity 
for their own signal peptides, there have been documented reports of chaperone 
promiscuity when the cognate chaperone is missing for a substrate, as in the case 
where DmsD is able to bind both preprotein forms of DmsA and TorA (57).  Utilizing 
the YFP-BiFC system developed for DmsA/DmsD interactions, we probed the 
specificity of the TorD and NarJ chaperones for their own cognate substrates and also 
for their ability to recognize non-cognate substrates (Figure 1.8 B).   
 The signal peptides of TorA and NarG were fused C-terminally to the Y1 
fragment (creating ssTorA-Y1, ssNarG-Y1), while the chaperones, TorD and NarJ 
were fused C-terminally to the Y2 fragment (creating TorD-Y2, NarJ-Y2).  
Coexpression of all three chaperones with their cognate or non-cognate substrates in 
wt TG1 cells resulted in all three chaperones cross reacting with ssDmsA-Y1 to 
varying degrees with a YFP-BiFC fluorescent signal intensity on the order DmsD >> 
TorD > NarJ.  The signal intensity of ssTorA-Y1/TorD-Y2 YFP-BiFC was only 35% 
of that for ssDmsA-Y1/DmsD-Y2 while no detectable fluorescent signal was observed 
above the negative control for the ssNarG-Y1/NarJ-Y2 YFP-BiFC.  This lack of 
fluorescence for the interaction between ssNarG/NarJ, can be attributed to the 
differences in experimental methods and conditions (in vivo detection versus in vitro) 
and to the stability of the substrates (engineered chimeras versus native proteins) when 
they are fused to the YFP fragments.   
 Overall, this data corroborates previously published evidence that the Tat 
pathway chaperone TorD can cross associate with non-cognate signal peptides and 
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create a degree of protein redundancy within the Tat pathway.  This data additionally 
demonstrates the flexibility and dynamic sensitivity of the YFP-BiFC assay where 
proteins of interest can be easily interrogated and their interacting partners can be 
evaluated in an in vivo setting.        
 
1.5 Detection of machinery-machinery interactions 
 After thoroughly interrogating the soluble protein interactions that occur in the 
cytoplasm of the E. coli Tat pathway we now turn the YFP-BiFC assay to monitor the 
transmembrane protein components (TatA, TatB, and TatC) that make up the Tat 
translocon and which are essential for Tat export (see Figure 1.3 B and C).  As 
mentioned previously, deletion of any component of the Tat translocon will result in a 
phenotypic change from single rod-shaped cells to elongated filamentous chains due to 
the cell wall amidase lpxC that is not exported into the periplasm by the Tat pathway 
(30).  Since we previously made and tested YFP-BiFC in Tat machinery deletion 
strains (e.g. ssDmsA-Y1/DmsD-Y2 in Figure 1.7) our first set of experiments was to 
investigate if the chain phenotype could be complemented and single rod-shaped cells 
could be detected by brightfield microscopy analysis.  We therefore tested the ability 
of each Tat component when fused to a YFP fragment (either Y1 or Y2) to 
complement the chain phenotype in single Tat machinery knockout strains (Figure 
1.9) by expressing the chimeric proteins in trans from a plasmid.   
 Fusion of the Y1 fragment to any of the Tat machinery components (e.g. TatA-
Y1) resulted in the inability to complement the chain phenotype.  However, fusion of 
the Y2 fragment, to either TatA-Y2 or TatC-Y2, or coexpression of the two fragments 
on homologous machinery components (TatA-Y1/TatA-Y2, TatC-Y1/TatC-Y2) 
results in the restoration of the singlet-rod-like cell phenotype seen for wt TG1 cells.  
It is important to note, that neither TatB-Y2 nor coexpression of TatB-Y1/TatB-Y2  
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could restore the singlet-rod-like phenotype.  This chain phenotype persistence in 
∆tatB TG1 cells could be a result of gene dosage effects since it is well known that 
TatB and TatC associate at near equal levels; both at native or over-expressed levels, 
when analyzed by in vitro methodologies (40,89-91).  With the Tat machinery 
Figure 1.9 Phenotype complementation of Tat mutants when expressing Tat-
machinery YFP fragment fusions.  Brightfield microscopy images of wt TG1, TG1 
∆tatAE, TG1 ∆tatB, and TG1 ∆tatC cells (left panels).  Expression of either Y1 or Y2 
fragments fused C-terminally to TatA, TatB, or TatC in the respective Tat mutants 
(center two panels).  Coexpression of both Y1 and Y2 fragments fused C-terminally to 
TatA, TatB, or TatC (right panel).    
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complementation data in hand, we applied YFP-BiFC to investigate the self-assembly 
of each Tat component in full knock out ∆tatABCE TG1 cells.  Previous experimental 
evidence has demonstrated that the self-assembly of individual Tat components in 
strains lacking all other tat genes is not dependent on the presence of other Tat 
components (92-94), however to obtain a more dynamic understanding of the Tat 
pathway in vivo through YFP-BiFC, we included the single knock out strains (∆tatAE, 
∆tatB, ∆tatC0) in our experiments.  Unless noted, the single knock out strains resulted 
in similar YFP-BiFC signals and results were reported for only the ∆tatABCE 
experiments.  TatA was our first Tat component for YFP-BiFC analysis. 
1.5.1 YFP-BiFC detection of TatA and F39A homo-oligomers   
 The E. coli TatA protein has been hypothesized as the channel through which 
substrates are exported into the periplasm and previous characterization studies have 
shown it to form stable, defined, homo-oligomeric complexes (41,42,95).  A ∆tatAE 
TG1 strain was created to ensure that only the chimeric TatA supplemented to the 
cells was plasmid based since TatA and TatE share 50% amino acid homology and 
have been shown to have similar protein export functions (96). 
 As mentioned previously, we created TatA fusion chimeras to the YFP 
fragments (TatA-Y1 and TatA-Y2), and coexpressed these constructs in either ∆tatAE 
or ∆tatABCE TG1 cells.  A fluorescent YFP-BiFC signal was detected, that localized 
to the polar regions (97) of ∆tatAE when observed under fluorescence microscopy 
(Figure 1.10) and when expressed in either ∆tatAE or ∆tatABCE had a signal intensity 
2-3 fold above the negative controls (Figure 1.11).  The YFP-BiFC signal intensities 
were roughly an order of magnitude lower than the observed signals for the ssDmsA-
Y1/DmsD-Y2 interactions.   
 We also investigated a well characterized TatA mutant, F39A that has a single 
amino acid substitution in a predicted amphipatic region which blocks translocation 
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Figure 1.10 Visualizing the formation of TatA homo-oligomers with YFP-BiFC.  
Brightfield and fluorescence microscopy for phenotypic analysis of chain 
complementation and fluorescence localization in TG1 ∆tatAE cells expressing 
various TatA chimeras as indicated.  Negative controls first two rows (e.g. TatA-
Y1/Y2, F39A-Y1/Y2).  F39A is E. coli TatA with a F39A mutation.  
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and leads to aberrant TatA homo-oligomer formation (36).  The F39A mutation was 
created in the TatA YFP-BiFC chimeras, generating F39A-Y1 and F39A-Y2, and 
when expressed in ∆tatAE cells could not complement the chain phenotype (Figure 
1.10).  Mixing the wt TatA-Y2 and F39A-Y1 mutant in ∆tatAE cells resulted in 
singlet cells with polar fluorescence localization, which was seen previously in the wt 
TatA YFP-BiFC.   
 Coexpression of F39A-Y1/F39A-Y2 in either ∆tatAE or ∆tatABCE TG1 cells 
resulted in a 2-fold increase in YFP-BiFC signal over the TatA-Y1/TatA-Y2 
(Figure1.11), a brighter signal intensity was also seen under fluorescence microscopy 
(Figure 1.10), however these complexes were non-functional since the chain 
phenotype was still present in ∆tatAE TG1 cells.  From this evidence, the export 
defect which characterizes F39A mutants is not a result of the inability to self 
assemble.   
Figure 1.11 Quantitative measurement of YFP-BiFC fluorescence for Tat homo-
oligomers.  Cell fluorescence of TG1 ∆tatABCE cells expressing TatA-Y1, TatA-Y2, 
F39A-Y1, F39A-Y2 and the negative controls Y1 or Y2 in various combinations 
shown above.  Median fluorescence values were obtained via FACS and reported as 
the average of 3 replicate measurements (n = 3).  
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1.5.2 Heterologous Tat machinery interactions detected with YFP-BiFC 
 As in the YFP-BiFC analysis of TatA interactions, we created chimeras for 
TatB (TatB-Y1/TatB-Y2) and TatC (TatC-Y1/TatC-Y2) and coexpressed these 
constructions in ∆tatABCE TG1 cells.  Only coexpression of TatB generated a YFP-
BiFC signal (Figure 1.12); no fluorescent signal over the negative controls was 
detectable for TatC self assembly which is consistent with earlier observations where 
the overproduction of TatC in the absence of all other Tat components resulted in low 
levels of TatC incorporation into the inner membrane (94).  The lack of YFP-BiFC 
signal for TatC self assembly is not due to the inactivity or instability of the chimeric 
proteins since the chain phenotype of ∆tatC is complemented resulting in singlet cells 
(Figure 1.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 YFP-BiFC assembly of TatBC homo- and hetero-oligomers.  (A) Cell 
fluorescence of TG1 ∆tatABCE cells coexpressing TatB and TatC chimeras as 
indicated above.  In addition to wt TatC, TatC variants (P48A, E103R) were also 
evaluated for YFP BiFC.  Unfused Y1 and Y2 were coexpressed with TatB, TatC, 
P48A, E103R and served as negative controls.  Median fluorescence values were 
obtained via FACS and are the average of 3 replicate (n = 3) measurements.  
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 Our next experiments were targeted at detecting heterologous Tat machinery  
interactions in ∆tatABCE TG1 cells.  Coexpression of different pairs of Tat 
components (e.g. TatA-Y1/TatC-Y2) in ∆tatABCE TG1 cells resulted in measurable 
YFP-BiFC fluorescence signals for TatA-Y1/TatB-Y2, TatA-Y1/TatC-Y2 and TatB-
Y1/TatC-Y2 (Figure 1.12) where the fluorescent signal obtained was 3-4 times that of 
the negative controls.  The results obtained are consistent with previously published 
findings where TatB and TatC associate as equimolar subunit complexes (40) and that 
TatB can interact with TatA in the absence of TatC (42).  Importantly, the YFP-BiFC 
signal can increase (TatC-Y2/TatB-Y1 versus TatC-Y1/TatB-Y2) or decrease (TatA-
Y1/TatC-Y2 versus TatA-Y2/TatC-Y1) depending on which chimeric protein fusion is 
expressing the Y1 or Y2 fragments, indicating possible steric hindrances and/or some 
Tat machinery components are more amenable to a certain YFP fragment. 
 In addition to examining the wt TatC interactions using the YFP-BiFC chimera 
proteins, we tested two TatC variants, P48A and E103R.  The P48A point mutation 
occurs in the first periplasmic loop region of TatC which abolishes substrate export 
and partially impairs TatC interaction with TatB (36), while the E103R point mutation 
lies in the first cytoplasmic loop between transmembrane helices II and III and blocks 
substrate export but does not affect the TatC interaction with TatB (98).  The chain 
phenotype of ∆tatC TG1 cells when transformed individually or co-transformed with 
YFP-BiFC chimera constructs P48A (Y1 or Y2) or E103R (Y1 or Y2) could not be 
complemented and no detectable YFP-BiFC signal was observed either by FACS or 
fluorescence microscopy (Figure 1.14 C). 
 When we coexpressed the P48A variant with TatB (e.g. P48A-Y1/TatB-Y2) 
and monitored their interactions with YFP-BiFC in ∆tatABCE TG1 cells, a notably 
marked decrease in fluorescence was seen, confirming that the interaction between the 
two proteins was impaired (Figure 1.12).  However, coexpression of the E103R 
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variant with TatB (e.g. E103R-Y2/TatB-Y2) resulted in near wt YFP-BiFC signals, 
again confirming previously published observations.           
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.3 TatBC YFP-BiFC interactions localize at cell poles 
 After obtaining a strong YFP-BiFC signal for TatB-Y1/TatC-Y2 and TatB-
Y2/TatC-Y1 interactions in ∆tatABCE TG1 cells (Figure 1.12) we examined the cells 
using fluorescence microscopy and could see a bright fluorescent signal at the cell 
poles (Figure 1.14 A).  We then co-transformed ∆tatB or ∆tatC TG1 cells with same 
plasmid combinations used for the ∆tatABCE experiment and we were able to see: a) 
the chain phenotype in both ∆tatB and ∆tatC TG1 cells was complemented resulting 
in singlet cells and b) the fluorescence signal from the YFP-BiFC was localized at the 
cellular poles (Figure 1.14 B and Figure 1.15 B).   
 The first result, complementation of the chain phenotype in ∆tatB or ∆tatC 
TG1 cells, supports previously seen experimental results with regards to the relative  
Figure 1.13 Expression of P48A and E103R YFP-BiFC chimera fusions in ∆tatC
cells.  Brightfield microscopy for phenotypic analysis of chain complementation in 
TG1 ∆tatC either for P48A or E103R TatC mutants fused to Y1 or Y2, expressed 
individual or together as indicated above. 
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amount of TatB and TatC, since overproduction of TatC alone will result in low levels 
of TatC integration into the inner membrane (94).  Additionally, since the formation of 
a fluorescent YFP protein in the YFP-BiFC assay is dependent on a 1:1 ratio of TatB 
and TatC associating, this further supports published experimental evidence that these 
proteins exist at equimolar concentrations (40).  Secondly, the localization of  
Figure 1.14 YFP-BiFC detection to TatBC hetero-oligomers in TG1 ∆tatABCDE 
and ∆tatB cells.  (A) Brightfield and fluorescence microscopy of TG1 ∆tatABCE 
coexpressing either TatB-Y1/TatC-Y2 or TatB-Y2/TatC-Y1.  (B) Brightfield 
microscopy for phenotypic analysis of TG1 ∆tatB as control cells or coexpressing 
TatB-Y1/Y2 or TatB-Y2/Y1 (middle row).  Brightfield and fluorescence microscopy 
of TG1 ∆tatB cells for phenotypic analysis of chain complementation and 
fluorescence localization of coexpressed proteins TatB-Y1/TatC-Y2 or TatB-
Y2/TatC-Y1 (bottom row).  
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fluorescence at the cellular poles when TatB and TatC chimeras are coexpressed for 
YFP-BiFC, gives the first in vivo experimental evidence that these proteins actually do 
associate at the poles.  Previously published evidence was only able to identify the 
individual TatB and TatC proteins at the poles, but not the two in unison (97).   
 Through the directed application of YFP-BiFC to membrane bound proteins, 
the in vivo interactions between homologous and heterologous transport machinery 
components in the Tat pathway of E. coli could be observed.  The dynamic range of 
the YFP-BiFC technique is sensitive enough to detect interactions between 
transmembrane proteins (e.g. TatA-Y1/TatA-Y2) or soluble cytoplasmic proteins (e.g. 
ssDmsA-Y1/DmsD-Y2), whereby the fluorescent signal intensity for the soluble 
interaction is an order of magnitude above that for the transmembrane interaction.  
Figure 1.15 YFP-BiFC detection of TatBC hetero-oligomers in TG1 ∆tatC cells.  
(A) Brightfield microscopy for phenotypic analysis of TG1 ∆tatC as control cells or 
coexpressing TatC-Y1/Y2 or TatC-Y2/Y1.  (B) Brightfield and fluorescence 
microscopy of TG1 ∆tatC cells for phenotypic analysis of chain complementation and 
fluorescence localization of coexpressed proteins TatB-Y1/TatC-Y2 or TatB-
Y2/TatC-Y1.   
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Additionally, we present the first experimental in vivo evidence that TatB and TatC 
co-localize at the poles of E. coli.     
 
1.6 Detection of substrate-machinery interactions 
 After utilizing YFP-BiFC to detect soluble protein interactions in the 
cytoplasm (e.g. ssDmsA-Y1/DmsD-Y2) and Tat translocon proteins associated with 
the inner membrane (e.g. TatA-Y1/TatC-Y2), we sought to detect interactions between 
a soluble Tat substrate and the Tat translocon.  The TatBC complex as examined with 
YFP-BiFC previously is known to interact with Tat pathway substrates (91,99) and act 
as a binding site before translocation into the periplasm.  The ability of a Tat substrate 
to associate with the inner membrane and subsequently interact with the Tat 
machinery components has been shown to be independent of Tat associated 
chaperones [(100)], therefore our next set of YFP-BiFC experiments tested the ability 
of ssDmsA to interact with TatB or TatC components.     
 Using the previously designed YFP-BiFC protein chimera constructs, we 
coexpressed ssDmsA-Y1 with TatB-Y2, TatC-Y2, P48A-Y2 or E103R-Y2 and used 
FACS analysis to monitor the fluorescent signal from the interacting proteins (Figure 
1.16) in a ∆tatABCE TG1 background.  Fluorescence was observed between ssDmsA-
Y1 and either TatB-Y2 or TatC-Y2, with an approximately 3.5 or 7 fold fluorescent 
signal above the negative control, respectively.  Full length DmsA-Y1 was also 
coexpressed with either TatB-Y2 or TatC-Y2 and a much weaker but still significant 
YFP-BiFC signal was observed.  No signal above background was observed when 
ssDmsA-Y1 was co-expressed with TatA-Y2. 
 To demonstrate a loss of YFP-BiFC, we took the two TatC variants described 
previously in Section 1.5.2, and we coexpressed ssDmsA-Y1 with either P48A-Y2 or 
E103R-Y2 in ∆tatABCE TG1 cells.  The resulting YFP-BiFC signal was 1.5-2.0 fold 
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less fluorescent that that seen for the wt TatC interaction (Figure 1.16).  These two 
mutations inhibit the export of substrates into the periplasm, which should cause a 
buildup of potential YFP-BiFC interactions and should generate a larger fluorescent 
signal.  However this increase in fluorescence signal does not occur, and can be 
explained by recent experimental data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
which indicates that E103R has a reduced binding affinity to substrates (98).  We 
hypothesize this same reduced binding affinity exists for the P48A TatC variant 
resulting in a lower fluorescence signal.  The decrease in fluorescent YFP-BiFC signal 
demonstrates that the YFP-BiFC is dependent on the affinity between the interacting 
proteins to generate a signal and not on the affinity between the YFP fragments.  
Figure 1.16 YFP-BiFC reveals ssDmsA interacting with TatB and TatC.  (A) Cell 
fluorescence of TG1 ∆tatABCE cells coexpressing ssDmsA-Y1, ssDmsA(KK)-Y1 
with TatB-Y2, TatC-Y2, P48A-Y2, or E103R-Y2 as indicated.  Y1 unfused but 
coexpressed with Y2-chimeras was used as a negative control.  Median fluorescence 
values were obtained via FACS and reported as the average of 3 replicate 
measurements (n = 3).  
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 Interestingly, when we tested the ability of ssDmsA(KK)-Y1 to interact with 
either TatB-Y2 or TatC-Y2 we observed a marked increase in YFP-BiFC signal that 
was 5.4- and 10.7-fold above background (Figure 1.16).  This corroborates the recent 
observation that the twin-arginine residues of the Tat consensus motif are not essential 
for binding of the precursor substrate to the TatBC complex (98), however these 
residues are necessary for transport into the periplasm (101), demonstrating a highly 
specific motif recognition ability by the Tat pathway. 
 
1.7 Detection of chaperone-machinery interactions 
 The last set of interactions that we wished to monitor with YFP-BiFC was 
between the soluble cytoplasmic proofreading chaperone DmsD and the TatBC 
components of the Tat translocon.  Utilizing the previously constructed TatB and TatC 
YFP-BiFC chimeras, with one additional construct DmsD-Y1, we coexpressed these 
protein fusions in ∆tatABCE TG1 cells and detected a YFP-BiFC signal between 
DmsD, TatB and TatC (Figure 1.17). 
 As in the ssDmsA-Y1 YFP-BiFC experiment, the DmsD interaction with TatB 
or TatC resulted in a 2-4 fold increase in fluorescent signal above background.  The 
YFP-BiFC signal, as in other cases tested, was shown to be negligibly affected when 
the orientation of the YFP fragments was changed (e.g. DmsD-Y1/TatC-Y2 versus 
DmsD-Y2/TatC-Y1.  Interestingly, when the DmsD chimera was coexpressed with 
either P48A or E103R, a dramatic decrease in YFP-BiFC signal over the wt TatC 
interaction was seen.  This result suggest that mutations to either of these residues in 
TatC, affects the manner in which DmsD interacts with the Tat translocon and on a 
larger scale how the transfer of the substrate (e.g. DmsA) can be impaired and 
translocation can be blocked.     
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1.8 Discussion 
 Bacterial protein export requires a wide range of protein interactions between 
soluble and transmembrane proteins. The rate limiting step in understanding these 
protein pathways in vivo has been the development of a dynamic reporter that can 
probe these interactions directly.  Here we have demonstrated that YFP-BiFC is such 
an in vivo reporter that has enabled us to detect numerous protein-protein interactions 
along the entirety of the Tat pathway in E. coli.  Specifically, we have observed 
interactions between a) soluble cytoplasmic proteins, b) homologous or heterologous 
transmembrane proteins and c) soluble cytoplasmic proteins with transmembrane 
proteins.          
Figure 1.17 YFP-BiFC reveals DmsD interacting with TatB and TatC.  Cell 
fluorescence of TG1 ∆tatABCE cells coexpressing DmsD-Y1 or DmsD-Y2, with 
TatB, TatC, P48A, or E103R chimeras as indicated.  Y1 or Y2 unfused but 
coexpressed with the other protein chimeras was used as a negative control.  Median 
fluorescence values were obtained via FACS and reported as the average of 3 replicate 
measurements (n = 3).  
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 Utilizing a simple two plasmid expression system for YFP-BiFC and varying 
the protein of interest, while keeping the linker region and YFP fragments constant, an 
unlimited number of interactions can be probed.  The dynamic range of YFP-BiFC, in 
terms of fluorescence intensity, spans an order of magnitude (eg. ssDmsA-Y1/DmsD-
Y2 versus ssDmsA-Y1/TatC-Y2) and could be expanded by a) altering the geometry 
of the flexible linker between the protein of interest and the YFP fragment and b) 
engineering the YFP fragments themselves for increased solubility and quantum yield.   
 With our proof of concept proteins, DmsA and DmsD, we validated that the 
application of YFP-BiFC to the Tat pathway is indeed feasible. We then expanded our 
experiments to validate previously determined interactions and also gained new 
insight into the ways that the E coli Tat pathway functions in vivo.  Beginning with 
substrate and chaperone protein interactions, we were able to observe that the initial 
association is governed by signal peptide recognition, but there were measurable 
differences in the emitted fluorescence from YFP-BiFC for signal peptides versus full 
length protein interactions (e.g. ssDmsA versus DmsA).  Additionally, substrate-
chaperone associations are not limited to their cognate substrates, but there is a degree 
of flexibility and redundancy within the Tat pathway that allows for a cross talk to 
occur so that substrates can be directed towards the Tat translocon.  
 Within the Tat translocon, transmembrane protein interactions both 
homologous and heterologous were observed by YFP-BiFC.  Association between the 
TatABC proteins was confirmed as previously reported, but more importantly the 
signal intensity from the YFP-BiFC varied depending on which two transmembrane 
proteins were being interrogated.  Mutations to components of the Tat translocon 
demonstrated that the YFP-BiFC signal had a dynamic range, by increasing (e.g. 
F39A) or decreasing (e.g. P48A and E103R) in fluorescence intensity, respectively.  
Finally, for the first time experimentally, we were able to demonstrate in vivo through 
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YFP-BiFC that TatB and TatC co-localize to the poles of E. coli.   
 Our final set of experiments with YFP-BiFC probed the interactions between 
soluble cytoplasmic proteins and their association with transmembrane Tat translocon 
proteins.  Both substrate (ssDmsA) and chaperone (DmsD) were able to interact with 
either TatB or TatC and upon visualization of the interaction by fluorescence 
microscopy, a fluorescent signal at the poles was observed.  These findings 
collectively provide the first genetic evidence that DmsD may play a role as a 
targeting factor that delivers substrates to the TatBC complex.  Additionally, when 
either DmsA or DmsD chimeras were coexpressed with the mutated TatC proteins 
(e.g. P48A and E103R), a decrease of YFP-BiFC fluorescence was observed, 
supporting the idea that TatC can interact with both substrate and chaperone before 
any translocation events occur.  Delineating the temporal sequence of interactions 
between these proteins cannot be accomplished using the method of YFP-BiFC due to 
the irreversible association between the YFP fragments and the time required for the 
YFP chromophore to form. 
 In conclusion, we have validated previously characterized protein interactions 
and uncovered new evidence for protein associations and spatial localization in the E. 
coli Tat pathway using the in vivo method of YFP-BiFC.    
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1.9 Materials and Methods 
1.9.1 Bacterial strains, growth and induction conditions.  
 The bacterial strains that were used in this study are described in Table 1.1.  
For cloning purposes E. coli MC4100 cells were grown aerobically in either liquid LB 
media or on solid LB media with agar added.  For the BiFC assay, TG1 cells were 
made electrocompetent by standard methods (102), transformed with equal plasmid 
concentrations, and grown overnight on solid LB media and antibiotics (BD 
Diagnostic Systems) at 37°C. 
 The next morning individual colonies were picked from the plates, placed into 
3-mL of liquid LB with antibiotics in 16-18mm culture tubes, and grown aerobically 
for 4 hrs at 37oC and 200 rpm or until the OD600 ~0.5.  Isopropyl β-D-thiogalactoside 
(IPTG) was added to a final concentration of 1mM for induction of protein expression, 
the culture was then moved to a room temperature (RT) incubator (20-24oC) at 200 
rpm for the next 8 hours.  Fluorescence was only observed for cells grown at RT, not 
at 37oC. 
 All single knock out TG1 Tat mutants were generated by P1 transduction from 
the Keio collection (103) and kanamycin resistance was removed as described (104).  
Strain TG1 ∆tatABCE was first created by P1 transduction of ∆tatE::KanR from the 
Keio collection; the kanamycin resistance was removed as described previously, and 
P1 transduction was done again from BW25113 ∆tatABC::aac (32) whereby the 
apramycin resistance was not be removed.   
 Antibiotic selection was maintained for all markers on plasmids at the 
following concentrations: ampicillin, 100µg/ml; chloramphenicol, 20µg/ml; 
kanamycin, 50 µg/ml; and tetracycline, 10 µg/ml.   
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Table 1.1 Strains used in this study. 
Strain Description Reference 
    MC4100 F’ araD139 ∆(argF-lac)U169 rpsL150 (Strr) 
relA1 flbB5301 deoC1 ptsF25 rbsR 
Laboratory 
stock 
    TG1 
 
F’ traD36 lacIq∆(lacZ) M15 proA+B+ / supE 
∆(hsdM-mcrB)5 (rk - mk - McrB-) thi ∆(lac-
proAB) 
Laboratory 
stock 
    TG1 ∆tatAE TG1 derivative lacking the tatA and tatE 
genes 
This work 
    TG1 ∆tatB TG1 derivative lacking the tatB gene This work 
    TG1 ∆tatC TG1 derivative lacking the tatC gene This work 
    TG1 ∆tatE TG1 derivative lacking the tatE gene This work 
    TG1 ∆tatABCE TG1 ∆tatE derivative with an apramycin 
marked deletion ∆tatABC::aac  
This work 
1.9.2 Construction of plasmids.   
Proof of concept interacting proteins chosen for YFP-BiFC experiments are 
dmsD and its cognate substrate dmsA. E. coli dmsD was polymerase chain reaction 
(PCR) amplified and cloned into the XbaI and KpnI sites of pKNT25 (105); generating 
pDmsDT25 that harbors a chimerical gene encoding dmsD fused to the T25 fragment 
of the catalytic domain of Bordetella pertussis adenylate cyclase. Similarly, plasmid 
pssDmsALT18 was constructed by cloning a PCR fragment encoding the signal 
peptide of dmsA (excluding the signal peptide cleavage site) into the PstI and KpnI 
sites of pUT18.  
To establish the BiFC assay system, PCR fragments encoding the N-(1-157aa) 
and C-terminal (158-238aa) halves of the enhanced yellow fluorescent protein (YFP), 
which were abbreviated as Y1 and Y2 hereafter, were amplified from pIAF817YFP (a 
gift from Dr. Rolf Morosoli).  Plasmids pDmsD-Y2 and pssDmsA-Y1 were 
constructed by replacing the T25 and T18 fragments in plasmids pDmsDT25 and 
pDmsALT18 with Y2 and Y1, respectively. The linker sequences used for the fusion 
proteins are designed on the basis of those used by Hu et. al. (106).  Further plasmid 
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constructions used in this and subsequent studies are based on these two initial 
plasmids. 
For the RFP BiFC assay, mRFP1 with the Q66T point mutation was split at the 
same amino acid location as described previously (107), generating two fragments 
abbreviated as R1 and R2.  These fragments were cloned in place of the Y1 and Y2 
fragments in the pssDmsA-Y1 and pDmsD-Y2 plasmids, respectively.    
Typical PCR reaction volumes were 50µL and genes cloned into plasmid 
vectors were either amplified from laboratory stock plasmids or from E. coli genomic 
DNA. VentR® Polymerase (New England Biolabs Inc, MA) was used for PCR on a 
BioRad Gradient Cycler (BioRad, CA).  DNA purification from agarose gel 
electrophoresis or enzymatic digestions was carried out using QIAquick Spin Kits 
(Qiagen, CA) and QIAprep Miniprep Kits (Qiagen, CA) were used for plasmid 
purification.  Restriction digestions using required enzymes were carried out as 
directed in the literature (New England Biolabs Inc, MA) and 20µL ligation reactions 
were carried out using T4 DNA Ligase (New England Biolabs Inc, MA).   
Electroporation of plasmid DNA was carried out using a Gene Pulser Xcell 
microbial system (BioRad, CA) following the preset bacterial transformation protocol 
(1.8kV, 25µF, 200Ω) for a 1mm-gap electroporation cuvette.  Plasmid constructions 
were carried out in MC4100 cells and sequence verified by the Cornell Life Sciences 
Core Laboratories Center.  All plasmids have been annotated and all plasmids used in 
this study are listed in Table 1.2. 
Table 1.2 Plasmids used in this study.  
Plasmid Description Reference
    pUT18 Plasmid containing T18 fragment of the 
catalytic domain of B. pertussis adenylate 
cyclase; AmpR 
(105) 
    pKNT25 Plasmid containing T25 fragment of the 
catalytic domain of B. pertussis adenylate 
cyclase; KanR 
(105) 
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Table 1.2 (Continued) 
    pssDmsALT18 E. coli dmsA signal peptide inserted into 
pUT18 
This work
    pDmsDT25 E. coli dmsD coding sequence inserted into 
pKNT25 
This work
    pssDmsA-Y1 pDmsALT18 with T18 sequence replaced by 
sequence encoding YFP N-terminal fragment; 
FLAG tag epitope at 3' end 
This work
    pDmsD-Y2 pDmsDT25 with T25 sequence replaced by 
sequence encoding YFP C-terminal fragment 
This work
    pY1 Control plasmid expressing Y1-FLAG; made 
by removing dmsA signal peptide sequence 
from pssDmsA-Y1 
This work
    pY2 Control plasmid expressing Y2; made by 
removing DmsD from pDmsD-Y2  
This work
    pssPhoA-Y1 pDmsA-Y1-FLAG with dmsA signal peptide 
sequence replaced by DNA encoding the 
signal peptide of the E. coli phoA gene 
This work
    pDmsA-Y1 pssDmsA-Y1 with dmsA signal peptide 
sequence replaced by full-length E. coli dmsA 
This work
    pssDmsA(KK)-Y1 pssDmsA-Y1 with RR to KK substitution This work
    pDmsA(KK)-Y1 pDmsA-Y1 with RR to KK substitution  This work
    pDnaK-Y2 pDmsD-Y2 with dmsD replaced by E. coli 
dnaK sequence 
This work
    pTorD-Y2 pDmsD-Y2 with dmsD replaced by the E. coli 
torD sequence 
This work
    pNarJ-Y2 pDmsD-Y2 with dmsD replaced by the E. coli 
narJ sequence 
This work
    pssTorA-Y1 pssDmsA-Y1 with dmsA signal peptide 
sequence replaced by E. coli torA signal 
peptide sequence 
This work
    pssNarG-Y1 pssDmsA-Y1 with dmsA signal peptide 
sequence replaced by E. coli narG signal 
peptide sequence 
This work
    pTatA-Y1 pssDmsA-Y1 with full-length E. coli tatA 
sequence in place of dmsA signal peptide 
sequence 
This work
    pTatA-Y2 pDmsD-Y2 with the full length E. coli tatA 
sequence in place of dmsD 
This work
    pF39A-Y1 pTatA-Y1 with F39A substitution This work
    pF39A-Y2 pTatA-Y2 with F39A substitution This work
    pTatB-Y1 pssDmsA-Y1 with full-length E. coli tatB 
sequence in place of dmsA signal peptide 
sequence 
This work
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Table 1.2 (Continued) 
    pTatB-Y2 pDmsD-Y2 with the full length E. coli tatB 
sequence in place of dmsD 
This work 
    pTatC-Y1 pssDmsA-Y1 with full-length E. coli tatC 
sequence in place of dmsA signal peptide 
sequence 
This work 
    pTatC-Y2 pDmsD-Y2 with the full length E. coli tatC 
sequence in place of dmsD 
This work 
    pP48A-Y1 pTatC-Y1 with P48A substitution This work 
    pP48A-Y2 pTatC-Y2 with P48A substitution This work 
    pE103R-Y1 pTatC-Y1 with E103R substitution This work 
    pE103R-Y2 pTatC-Y2 with E103R substitution This work 
    pDmsD-Y1 pssDmsA-Y1 with dmsD in place of dmsA 
signal peptide sequence 
This work 
    pR1 pY1 with mRFP1 Q66T N-terminus in place of 
Y1; FLAG epitope at 3’ end  
This work 
    pR2 pY2 with mRFP1 Q66T C-terminus in place of 
Y2 
This work 
    pssDmsA-R1 pssDmsA-Y1 with N-terminus of mRFP1 
Q66T in place of dmsA signal peptide 
sequence 
This work 
    pDmsD-R2 pDmsD-Y2 with C-terminus of mRFP1 Q66T 
in place of dmsA signal peptide sequence 
This work 
    pDmsD-Y2-SsrA pDmsD-Y2 re-cloned to express Y2 with a C-
terminal SsrA tag 
This work 
    pssTorA-GFP- 
   SsrA 
ssTorA-GFP-SsrA; CmR  (108) 
    pDmsD-Y2 TetR KanR marker in pDmsD-Y2 replaced with TetR 
marker 
This work 
    pY2 TetR KanR marker in pY2 replaced with TetR marker This work 
    pTatB-Y2 TetR KanR marker in pTatB-Y2 replaced with TetR 
marker 
This work 
    pTatC-Y2 TetR KanR marker in pTatC-Y2 replaced with TetR 
marker 
This work 
    pP48A-Y2 TetR KanR marker in pP48A-Y2 replaced with TetR 
marker 
This work 
    pE103R-Y2 TetR KanR marker in pE103R-Y2 replaced with TetR 
marker 
This work 
1.9.3 DmsD-Y2-SsrA construction and expression.  
 Primer extension PCR was performed to attach the coding sequence for the 
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SsrA degradation tag (AANDENYALAA) to the 3’ end of Y2 which was then cloned 
into the pDmsD-Y2 plasmid, replacing the original Y2 fragment, and creating the 
construct pDmsD-Y2-SsrA.  pDmsD-Y2-SsrA was then co-transformed with Y1 
carrying plasmids into TG1 wt cells and plated overnight as described previously.  
After induction as previously described, the cells were analyzed via FACS for 
fluorescence at 8 hrs, then harvested by centrifugation (10000 x g, 10min, 4ºC) and 
resuspended in the same volume of fresh LB with antibiotics and without IPTG.  The 
cells were returned to the 200 rpm shaker at RT and allowed to equilibrate for another 
8 hrs before a final FACS reading for fluorescence was taken.          
1.9.4 Fluorescence measurements, microscopy, and image processing.  
 After induction of protein expression, FACS data was collected on a BD 
FACSCalibur System (Franklin Lakes, NJ) at 0 and 8 hours post induction (Figure 
1.18).  Samples for FACS readings were prepared by diluting 50 µl of live bacterial  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18 Gating of FACS data for TG1 wt and ∆tatABCE cells.  Cell 
fluorescence collected by FACS for TG1 wt (panel 1 and 2) or TG1 ∆tatABCE (panel 
3 and 4) cells coexpressing ssDmsA-Y1/DmsD-Y2.  Panel 1 and 3 represent the 
forward and side scatter signals with the FACS gate (indicated by the black circle) that 
was used to count fluorescent cells.  Panel 2 and 4 are histograms derived from panel 
1 and 3, respectively, whereby these histograms are representative of the YFP-BiFC 
signal from the FL1-H FACS detector.   
 43 
cells directly from culture in 1mL of 1x phosphate buffered saline (PBS).  The FACS 
gate was then situated between the forward scatter detector (FSC-H) and side scatter 
detector (SSC-H) as indicated by the black circle for panels 1 and 3 in Figure 1.18.  
From the cells that passed through this gate, fluorescence measurements for YFP-
BiFC were obtained by the FL1-H FACS detector.  The fluorescence measurements 
were collected in replicates as indicated in the figures and the mean of the median 
fluorescence value was reported.   
 For RFP fluorescence measurements, the Biotek Synergy HT Plate Reader was 
used whereby 100µl of bacterial cells were spun down, washed twice with 1mL of 1x 
PBS, and resuspended in 150 µl of 1x PBS and placed into a Costar clear bottom-
black side wall 96-well plate (Corning, NY).  Fluorescence readings were taken with 
an excitation filter 530/25, emission filter 590/35, bottom detector setting, and 
sensitivity setting of 50.   
 For microscopy, 15µl of live bacterial cells directly from culture were placed 
onto a microscope slide with cover slip.  All images were taken under oil immersion 
microscopy using a Zeiss 100x/1,30 lens.  Microscopy was performed on a Zeiss 
Axioskop 40 equipped with a Zeiss 100x/1,30 Oil Plan-NEOFLUAR lens, a EXFO X-
Cite light source (Mississauga, Ontario), a Semrock Brightline filter cube for YFP 
emission (YFP-2427A-ZHE) or RFP emission (Cy3-4040B-ZHE) (Rochester, NY), 
digitally imaged with a SPOT FLEX digital camera from Diagnostic Instruments, Inc. 
(Sterling Heights, MI) and controlled with Spot Imaging Software (Sterling Heights, 
MI).  All images captured under 100x-oil immersion microscopy using the Zeiss 
100x/1,30 Oil Plan-NEOFLUAR lens were under brightfield illumination (exposure 
150ms) or under UV illumination (exposure 500ms). Images were saved as .tiff file 
format, imported into Adobe Photoshop (San Jose, CA), cropped and resized to 
400x400 pixels, gray scale and auto leveled (bright field images only), imported into 
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Adobe Illustrator (San Jose, CA), scaled to 30% of 400x400 pixel size for the resulting 
figures. 
1.9.5 Cellular fractionation and Western blotting.  
 After 8 hours of induction, 1ml of cells was taken and the OD600 was measured 
using a Biomate3 spectrophotometer (Thermo Scientific, MA).  The cells were then 
spun down for 2 min at 13,000 x g and the supernatant was removed.  The periplasmic 
fraction from the E. coli cells was isolated by using a modified protocol of the 
Epicentre Biotechnologies PeriPreps™ Periplasting Kit (Madison, WI), where the 
periplasting buffer did not contain any Ready-Lyse Lysozyme.  The soluble protein 
fraction from the periplasmically treated E. coli cells was isolated with BugBuster® 
Master Mix (Novagen, Madison, WI) via the supplied Novagen protocol.   
 For Western blotting, an equal volume of 2x SDS-PAGE buffer was added to 
the periplasmic and soluble protein fractions and then boiled for 15 min at 100ºC.  
Samples were loaded onto 4-20% iGels (NuSep Ltd, Australia) where protein amount 
was normalized to the optical density of the cells taken before fractionation.  After 
SDS-PAGE, the proteins were transferred to Immobilon-P PVDF 0.45µm membrane 
(Millipore, MA) and probed for the epitope FLAG (DYKDDDK) tag for Y1 fusions 
using the primary antibody Anti-FLAG® M2 (Stratagene, CA) with secondary 
antibody being Anti-Mouse IgG-HRP (Promega, WI).  To detect the Y2 fragment, the 
primary antibody was anti-GFP (Roche, IN) with secondary Anti-Mouse as described 
above.  As a cytoplasmic fractionation marker, the primary antibody Anti-GroEL 
(Sigma, MO) was used along with the secondary Anti-Mouse as described above.  
HRP detection was done by chemi-luminescence using the Immun-Star HRP 
Chemiluminescent Kit (BioRad, CA) and captured on Kodak X-Omat Film 
(Rochester, NY).       
 
 45 
CHAPTER 2 
 
SCREENING A LIBRARY OF DMSD BINDING POCKET MUTANTS FOR 
INCREASED AFFINITY TO DMSA WITH YFP-BiFC 
 
2.1 Introduction 
 Bacterial protein evolution has been occurring over the last few billion years 
and proteins continue to evolve due to the selective pressures in the local environment.  
Evolution of these proteins at the genetic level occurs through in a variety of manners, 
a) random mutagenesis (e.g. UV exposure, DNA polymerase errors) leading to base 
pair insertions, deletions, transitions or transversions, b) through bacterial conjugation, 
c) transduction of genetic material by bacteriophage and d) transformation by uptake 
of DNA in the local environment (109).  Within the last few decades, recombinant 
DNA technologies have emerged whereby the DNA coding for the protein of interest 
can be isolated, mutated, and subsequently the protein itself can be expressed (110).  
In this manner, proteins can be evolved in vitro at rates much higher than those seen in 
nature.  One of the largest challenges faced by in vitro protein evolution is linking the 
phenotype (e.g. the activity of the protein) with the genotype (e.g. the proteins’ DNA 
coding sequence). 
 To overcome this phenotype-genotype linkage problem, numerous reporter 
systems have been developed such as, a) ribosome display (111), b) phage display 
(112) and c) intrabody selection after Tat export (ISELATE) (113,114).  Subsequently,  
large in vitro DNA libraries for specific proteins (e.g. single chain variable fragment 
(scFv) antibodies (113,115-118)) were generated and these reporter systems were 
applied to specifically detect proteins that had enhanced characteristics over the native 
protein of interest. 
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 From our previous experimental results using the YFP-BiFC assay to monitor 
protein interactions in vivo in the E. coli Tat pathway, we observed that the fluorescent 
signal from YFP-BiFC interactions was dynamic and spanned an order of magnitude 
(e.g. DmsA-Y1/DmsD-Y2 versus TatA-Y1/TatA-Y2) depending on the type of protein 
interactions interrogated.  Since the YFP-BiFC assay maintains a phenotype-genotype 
linkage through the expression of protein chimeras from a two plasmid system, cells 
with a specific phenotype can be recovered and their plasmids analyzed to detect 
genetic mutations that result in the observed phenotype.  Therefore using this linkage 
we screened a plasmid library of DmsD mutants for an increase in YFP-BiFC signal 
that would arise from an increased affinity to ssDmsA. 
  
2.2 Site directed mutagenesis of binding pocket residues in DmsD using an NNK 
primer library approach 
 To demonstrate the utility of our YFP-BiFC assay beyond screening natural 
components of the Tat system, we next sought to isolate gain-of-function DmsD 
variants that bind ssDmsA more efficiently, resulting in an increased YFP-BiFC 
signal.  Previous studies utilizing in silico bioinformatic methods identified a “hot 
pocket” of residues which were conserved across numerous bacterial species 
possessing the homologous protein DmsD (Table 2.1).  These “hot pocket” residues, 
referred to as binding pocket pt. 1 and pt. 2 (Table 2.1) were shown to be important for 
binding to the signal peptide of DmsA (1,119).  Additionally the crystal structure of 
DmsD from Salmonella typhimurium was determined (Figure 2.1) allowing for an 
unprecedented view of the chaperone at a 1.38 Angstrom resolution (120).  Using both 
of these resources, we went ahead and examined if we could screen a DmsA-
Y1/DmsD-Y2 library using YFP-BiFC. 
 From published experimental data by Chan et. al. 2008 (1), two variants of  
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DmsD were isolated; a) a lower affinity (compared to wt DmsD) double substitution 
mutant R15C/L75S and b) a hyperbinding variant of DmsD carrying a single amino 
acid substitution, W87Y, which was reported to bind ssDmsA at a level that was 1.5 
times above that of wt DmsD when using a bacterial-two-hybrid assay (1).  As a 
proof-of-concept, we created these mutant DmsD-Y2 chimeras (R15C/L75S and 
W87Y) for YFP-BiFC analysis, and co-expressed them with either ssDmsA-Y1 or 
DmsA-Y1 in wt TG1 cells.  In agreement with the observations seen in Chan et. al., 
the R15C/L75S mutant exhibited a decreased binding affinity to ssDmsA (i.e. a lower 
YFP-BiFC signal compared to wt DmsD), while the W87Y mutant had an increased 
affinity and in turn a higher YFP-BiFC signal compared to wt DmsD (Figure 2.2 A 
and B).  Importantly, when these two DmsD mutants were coexpressed with full 
length DmsA, no fluorescence signal change was observed with YFP-BiFC when 
Table 2.1 Residues in DmsD involved in the binding of ssDmsA.  Table adapted 
from Chan et. al. 2008 (1).  After bioinformatic analysis, residues (x) were mutated 
using a site-directed kit and their ability to bind ssDmsA was interrogated with an in 
vitro dot-blot far-Western screen.  Residues in bold showed a decrease in binding of 
ssDmsA compared to wt DmsD.  Redox Enzyme Maturation Protein (REMP) familes, 
of which DmsD is a member, contain the two conserved residue motifs.  The binding 
pocket in DmsD for ssDmsA consists of two parts, pt.1 (W72, L75, F76, P86) and pt. 
2 (P124, D126, H127, L151).   
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compared to ssDmsA.  This discrepancy can be explained initially by differences in 
experimental methods because both DmsD mutants (R15C/L75S and W87Y) were 
characterized for binding the signal peptide of DmsA, not full length DmsA.  
Additionally, the R15C/L75S mutation would have no affect on the YFP-BiFC signal 
because the full length DmsA-Y1 protein is 110kDa and undoubtedly interacts with 
other parts of the DmsD chaperone.  These interactions result in a lower free energy 
state for the substrate-chaperone pair and counteract the disruptive point mutation.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  DmsD binding pocket for ssDmsA.  Crystal structure of DmsD from 
Salmonella typhimurium by Qiu et. al. 2008 (2) (PDB ID 1s9u).  Entire protein 
colored in white.  Mutating residues colored in black (W76, F76, P124, H127) results 
in a decreased binding affinity to ssDmsA, while residues colored in gray (Y22, W87, 
E123) result in an increase in binding affinity for ssDmsA as demonstrated in Chan et. 
al. 2008 (1). Figure generated using PyMol (6).  
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Figure 2.2 Isolation of gain-of-function chaperones.  (A) Cell fluorescence of 
DmsD library isolates (HYF, YLF, FYL, IVT) when coexpressed with ssDmsA-Y1 or 
DmsA-Y1 (B) in wt TG1 cells.  Two previously characterized mutants (R15C/L75S, 
W87Y) were included for comparison.  Data normalized to ssDmsA-Y1/wt DmsD-Y2 
signal and unfused Y2 coexpressed with ssDmsA-Y1 was the negative control.  
Median fluorescence values obtained via FACS and averaged from 3 replicate 
measurements (n = 3).  (C) Western blot analysis of cytoplasmic (c) or periplasmic (p) 
fractions isolated from cells coexpressing ssDmsA-Y1 with DmsD-Y2 mutants as 
indicated.  GroEL served as a cytoplasmic fractionation marker.  
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2.3 Screening a DmsD library with YFP-BiFC to identify clones with increased 
affinity for DmsA 
 Confident that our YFP-BiFC assay was able to discriminate changes in 
binding, we created 2 random libraries of DmsD using an NNK library approach (N 
coding: A,C,G,T; K coding: G,T) that targeted residues W72/L75/F76 in binding 
pocket pt. 1 (119) after analyzing the crystal structure with PyMol (6). The resulting 
DmsD-Y2 library was coexpressed with either ssDmsA-Y1 or full-length DmsA-Y1 in 
wt TG1 cells.  After induction of protein expression for YFP-BiFC, the cells were 
screened via fluorescence activated cell sorting (FACS) for a fluorescent YFP-BiFC 
signal that was above the signal generated from wt DmsD-Y2/ssDmsA-Y1 or wt 
DmsD-Y2/DmsA-Y1 interactions. 
 The cells with higher YFP-BiFC signals were isolated and their plasmids 
containing the mutated variants of DmsD-Y2 were sequenced to identify the mutations 
generated by the NNK library.  As seen in Table 2.2, a strong bias for hydrophobic, 
uncharged residues in these positions was observed, especially in positions 72 and 76 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Mutants isolated from 3-NNK DmsD library screen.  The 3-amino acid 
variants isolated from the DmsD library are listed in the left column by their 3-letter 
designation.  The DmsD-Y2 mutants were tested for YFP-BiFC with ssDmsA-Y1 or 
DmsA-Y1 and the fluorescence intensity was normalized to wt DmsD-Y2/ssDmsA-
Y1 and reported as the binding activity for either ssDmsA or DmsA.   
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where a hydrophobic residue was found in 16/21 and 19/21 clones, respectively (7 and 
10 of these, respectively, were wt in this position). Position 75 appears to be the most 
flexible as more than half of the clones carried a hydrophilic residue in this position, 
and in 2 of these cases the residue was charged (Arg, Asp).  
 Interestingly, these 3 residues (aa 72, 75, 76) of DmsD could tolerate much 
greater structural variability when the binding partner was ssDmsA-Y1 (Table 2.2). 
This indicates that substrate binding specificity is dependent on the context of the 
signal peptide (i.e. alone versus affixed to full length DmsA) and that the sequence 
determinants for binding of the full length DmsA are much more specific compared to 
just the ssDmsA signal peptide alone. Thus, care must be taken when interpreting data 
from chaperone binding experiments where signal peptides are used as surrogates for 
the full-length pre-protein substrate. 
 After generating and screening the NNK-DmsD library (as described in the 
Materials and Methods Section) we identified clones that had an increased YFP-BiFC 
fluorescent signal over the ssDmsA-Y1/DmsD-Y2 interaction where DmsD was wild 
type.  From this screen we chose four mutants, named by their respective mutations 
(HYF, YLF, FYL and IVT) and coexpressed them with either ssDmsA-Y1 or DmsA-
Y1 in wt TG1 cells.  When the YFP-BiFC fluorescence data was normalized to the 
ssDmsA-Y1/wt DmsD-Y2 signal (Figure 2.2 A and B; Table 2.2), three of the mutants 
showed an increase in fluorescence (HYF, FYL, IVT) for the ssDmsA-Y1 chimera, 
while only mutants (YLF or FYL) demonstrated an increase in fluorescence for 
DmsA-Y1.  To validate that the increased YFP-BiFC fluorescence signal correlated to 
improved substrate binding rather than simply higher protein expression levels for 
DmsD, we Western blotted against the DmsD-Y2 chimera and determined that the 
expression level of each clone was unchanged relative to wt DmsD (Figure 2.2 C).   
 From the characterized DmsD library isolates, we were able to obtain mutants 
 52 
that showed a higher binding affinity to both the signal peptide and full length DmsA, 
validating that YFP-BiFC can be used as a tool to identify increased affinity mutants 
from a randomly generated library.  However this library only focused on half of the 
residues that exist in the binding pocket of DmsD limiting the amount of sequence 
space that could contain higher affinity DmsD mutants. 
 
2.4 Potential Future Library Screens 
 From the first NNK library screen, that targeted the three amino acids residues 
in the signal peptide binding pocket, we were able to demonstrate that enhanced 
variants of DmsD could be isolated with YFP-BiFC.  Our first NNK library however 
was limited in scope because it only targeted half of the signal peptide binding pocket.  
Two sets of experiments are proposed to identify better binding DmsD variants using 
YFP-BiFC as a screening tool. 
 The first experiment will expand the NNK library to include all of the residues 
that are in the binding pocket, therefore increasing the sequence space of available 
amino acids that can be present and subsequently interact with the signal peptide of 
DmsA.  The library size necessary to cover this sequence space is approximately 
6.4x107 clones, which is an acceptable and realistic size even for 3-fold coverage in E. 
coli.  The selectivity of the YFP-BiFC assay will only detect those DmsD-Y2 clones 
that are soluble and can bind to either the ssDmsA-Y1 or DmsA-Y1 protein, resulting 
in a reconstituted YFP protein whose fluorescence would then be detectable by a 
FACS machine; thereby automatically eliminating non-binding DmsD variants from 
the library.  DmsD clones isolated from this library can then be compared via DNA 
sequencing to determine if there are any consensus residues that result in increase of 
affinity to DmsA. 
 The second experiment is to quantify the relative affinities of the isolated 
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DmsD variants through surface plasmon resonance (SPR) experiments.  The affinity 
for wt DmsD to ssDmsA has been determined by SPR (121), therefore the isolated 
DmsD mutants can be characterized in this manner to determine if there is a detectable 
increase in the relative affinity.  This kinetic data could then be compared against the 
signal intensity observed in vivo for YFP-BiFC, and a correlation between affinity and 
signal intensity between the two experiments could be determined.  This experiment 
would provide quantitative evidence that YFP-BiFC can be used as a tool to identify 
increased affinity protein interactions.                     
 
2.5 Discussion 
 Utilizing the previously characterized interactions between DmsA and DmsD 
from Chapter 1 using YFP-BiFC, we wished to expand the utility of YFP-BiFC to 
detect increased affinity DmsD variants to DmsA.  As proof of concept experiments, 
we tested and confirmed previously characterized DmsD mutants with either 
decreased affinity (R15C/L75S) or increased affinity (W87Y) to ssDmsA using YFP-
BiFC analysis.  However, when we tested these same mutations against full length 
DmsA in the YFP-BiFC assay, we were not able to see an increase or decrease in 
signal intensity presumably due to interactions between sites outside of the binding 
pocket that stabilize the full length DmsA interaction with the DmsD chaperone. 
 With the proof of concept experiments validated, we created a 3-NNK library 
for amino acids located at positions 72, 75, and 76 in DmsD-Y2.  This library was then 
screened against either ssDmsA-Y1 or DmsA-Y1 in TG1 cells.  The cells were then 
sorted by FACS analysis and those DmsD-Y2 variants that exhibited a fluorescence 
YFP-BiFC signal over the wt DmsD-Y2 interactions were isolated and their DNA 
sequences were characterized.  From this library screen we were able to identify 
numerous DmsD variants that showed an increase in YFP-BiFC for both the signal 
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peptide and full length DmsA protein.   
 From these experimental results, we have demonstrated for the first time that 
YFP-BiFC can be used as a tool to identify protein interactions with increased affinity.     
 
2.6 Materials and Methods 
2.6.1 Bacterial strains, growth and induction conditions. 
Bacterial strains, growth, and induction conditions used in this study are 
described in Chapter 1.8, unless otherwise mentioned.    
2.6.2 Construction of plasmids. 
Previously used plasmids are described in Chapter 1.8, however additional 
plasmids used in this study are listed below in Table 2.3. 
Table 2.3 Plasmids used in this study. 
Plasmid Description Reference 
    pR15C/L75S pDmsD-Y2 with R15C and L75S mutations This work 
    pW87Y 
 
pDmsD-Y2 with W87Y mutation This work 
    pHYF pDmsD-Y2 library isolate with W72H, 
L75Y, F76F mutations 
This work 
    pYLF pDmsD-Y2 library isolate with W72Y, 
L75L, F76F mutations  
This work 
    pFYL pDmsD-Y2 library isolate with W72F, L75Y, 
F76L mutations 
This work 
    pIVT pDmsD-Y2 library isolate with W72I, L75V, 
F76T mutations  
This work 
2.6.3 DmsD NNK library construction.   
 Bioinformatic and in vivo experimentation by Chan et. al. 2008 demonstrated 
that a potential “hot pocket” of residues involved in binding the signal peptide of 
dmsA occurred at two sites in the protein dmsD; site number one (amino acids W72, 
L75, F76), site number two (E123, P124, D126, H127).  Using degenerate primers, 
MD1623 5’–GAA GAG ACT CAC GCC CAG GCC NNK CAG CGT NNK NNK 
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GTC GGC CCG TGG GCA CTG – 3’ and MD1624 5’ –  CAG TGC CCA CGG GCC 
GAC CGC GCT ACG CTG GCT GGC CTG GGC GTG AGT CTC TTC – 3’ 
(Integrated DNA Technologies, Inc., IA) whereby N (codes for A,C,G,T) and K 
(codes for G,T) with template plasmid pDmsD-Y2, we targeted the three residues in 
site number one with the Stratagene QuikChange II Site-Directed Mutagenesis Kit (La 
Jolla, CA).  The amplified product was transformed into XL-1 Blue cells resulting in 
~105 clones; representing a 3x library coverage.  XL-1 Blue cells were harvested, 
grown in liquid culture and midi-prepped using the PureYield ™ Plasmid Midiprep 
System from Promega (Madison, WI).   
 The 3-NNK DmsD library was then digested with SphI and KpnI to isolate the 
mutated DmsD library and ligated into clean KanR plasmid backbone to prevent any 
potential mutations in the plasmid backbone that could be detrimental to the 
expression of the gene fusion.  This second 3-NNK library was harvested and midi-
prepped and then electroporated into electrocompetent TG1 cells which contained 
either pssDmsA-Y1 or pDmsA-Y1 using 2-mm gap electroporation cuvettes with 
preset electroporation settings (2.5kV, 25µF, 200Ω).  This library was spread on LBA-
Amp/Kan plates and incubated overnight at 37ºC for resolution of transformants.   
2.6.4 Expression and isolation of enhanced affinity DmsD clones. 
After overnight incubation, the transformed cells were pooled into a 500mL 
culture, allowed to grow to and OD600 ~ 0.5 at 37ºC and 200 rpm, induced with 1mM 
IPTG, and grown for 8hrs at RT/200 rpm.  Aliquots of the culture were taken and 
diluted into one milliliter of 1x PBS and run through a BD FACSCalibur (Franklin 
Lakes, NJ) set for cell recovery mode.  The gate used on the FACSCalibur would only 
recover cells with a fluorescent signal greater than the wt ssDmsA-Y1/DmsD-Y2 or 
the wt DmsA-Y1/DmsD-Y2 BiFC signal. The recovered cells were concentrated on 
Whatman Sterile Membrane Filters, 0.45µm pore size (Kent, UK) and the membrane 
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filter was transferred to LBA Amp/Kan plates to allow for single colonies growth 
overnight at 37ºC.   
 Isolates from the overnight incubation were then picked off and grown in 96-
well culture plates to an OD600 ~0.5 at 37ºC and 200 rpm, induced with 1mM IPTG at 
RT/200 rpm for 8hrs.  Fluorescence was then measured using a Biotek Synergy HT 
Plate Reader (Winooski, VT) with excitation filter 485/20, emission filter 528/20, 
bottom detector setting, and sensitivity of 50.  Wells containing cells with a 
fluorescent signal greater than the wt ssDmsA-Y1/DmsD-Y2 or wt DmsA-Y1/DmsD-
Y2 signal were then re-grown, plasmid DNA was harvested and submitted for 
sequencing.  Selected sequences isolated from 96-well plates are listed in Table 2.2 
while gain of function DmsD-Y2 characterized plasmids are listed above in Table 2.3. 
2.6.5 Fluorescence measurements. 
Cell fluorescence measurements were obtained via FACS as previously 
described in Chapter 1.8. 
2.6.6 Cellular fractionation and Western blotting. 
 Cellular fractionation and Western blotting were performed as previously 
described in Chapter 1.8.  
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CHAPTER 3 
 
UTILIZING YFP-BiFC TO STABILIZE PROTEIN INTERMEDIATES FOR 
PURIFICATION AND CRYSTALLOGRAPHY 
 
3.1 Introduction 
 The ability to detect and monitor protein interactions in vivo is useful for 
understanding the macroscopic dynamics involved in intracellular systems.  However 
if a more detailed study of the protein of interest is required (e.g. enzyme kinetics), in 
vivo methods become a hindrance due to the complex number of interactions 
occurring in parallel within the organism.  Therefore it becomes a necessity to be able 
to isolate the protein of interest in a relatively short time span, to obtain a high purity 
sample of the protein without other protein contaminants, and most importantly 
perform these steps in an economically feasible manner for in vitro analysis. 
 The development of protein purification methods is a vast scientific area with 
numerous highly characterized methodologies and experimentally validated 
techniques, but it is also an area of continuous research and development.  Affinity 
chromatography, whereby the protein of interest is selectively removed from cellular 
lysates due to a specific affinity for an immobilized substrate (e.g. a metal ion) is by 
far the most common method used for protein purification (122,123).  Affinity 
chromatography methods are predominantly aimed at capturing a single protein of 
interest, but these methods can be modified to isolate protein complexes (57,124) that 
interact with the protein of interest; however some of these interactions are non-
specific due to the in vitro nature of the purification environment. 
 The YFP-BiFC assay as described previously is able to monitor protein 
interactions occurring in vivo; however as mentioned before, the reconstitution of the 
 58 
fluorescent protein YFP is irreversible under standard cellular conditions, resulting in 
the entrapment of the two interacting proteins.  Utilizing the irreversible characteristic 
of YFP-BiFC, we demonstrate experimentally for the first time that the full length 
DmsA protein interacting with its chaperone DmsD can be purified to highly pure 
concentrations using traditional metal-affinity column chromatography methods.             
        
3.2 YFP-BiFC – An irreversible association 
 The application of YFP-BiFC for the detection of protein-protein interactions 
in vivo is favored over other methods due to the assay’s ability to directly monitor the 
interactions of two proteins in their local cellular environment and for the inability of 
the fragments to fold spontaneously, which would result in false positive signals 
(64,125,126).  The folding of proteins is dictated by minimizing the free energy of the 
system (e.g. –∆Gfolded-unfolded state); therefore folding of the two YFP fragments is 
energetically favorable, resulting in a stable-folded protein.  This stability in turn ends 
up trapping of the two proteins of interest that are directly fused to the fragments and 
results in an irreversible association.     
 Since the YFP-BiFC assay is dependent on the affinity between the two 
proteins of interest, an interaction with a weak affinity will therefore not be detected.  
Using a leucine zipper library, the disassociation constant (KD) of ~ 1mM was 
determined to be the affinity limit for the YFP-BiFC assay (70).  Since the affinity 
between ssDmsA and DmsD is KD ~ 64µM (121), and a very strong fluorescent YFP-
BiFC signal is observed for both the signal peptide and full length protein, we 
hypothesized that the full length DmsA-DmsD-YFP complex could be isolated.        
  
3.3 Characterization of epitope tags for the purification of DmsA 
 To take advantage of the irreversible nature of the YFP-BiFC assay in 
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capturing protein interactions, we attached two common epitope tags to the C-
terminus of full length DmsA (Figure 3.1).  The FLAG (DYKDDDDK) (127) and His 
(HHHHHH) epitopes are highly immuno-reactive sequences that can be recognized by 
commercially available antibodies allowing for the quantitative analysis of 
recombinant protein production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Initially, we expressed full length DmsA with either a C-terminal FLAG or a 
HIS tag in ∆tatC TG1 cells to prevent the export of DmsA and cleavage of its signal 
peptide.  In both expression studies we were able to detect full length DmsA, albeit at 
drastically different levels (FLAG versus HIS respectively).  We additionally noted 
that a fair amount of degradation products were present, indicating that proteolytic 
degradation of the recombinant protein was occurring. 
 To alleviate the formation of degradation products, we coexpressed DmsD 
with DmsA fused to the two epitope tags at its C-terminus.  Since DmsD is a 
Figure 3.1 Using YFP-BiFC, substrate-chaperone pairs are stabilized and 
prevent proteolytic degradation.  Two Western blots probed with primary-HRP 
conjugated antibodies against epitope tags FLAG or 6x-HIS, respectively.  Either a 
FLAG tag or 6x-HIS repeat was cloned as a C-terminal fusion to full length DmsA or 
the YFP-BiFC chimeric DmsA-Y1.  The DmsA constructs were expressed with either 
DmsD or DmsD-Y2 in ∆tatC TG1 cells.  Only the soluble fraction was loaded for 
Western blot analysis.   
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chaperone, coexpression of this protein would provide protection from premature 
proteolytic cleavage of the signal peptide and it also would assist in stabilizing DmsA 
while it attains its tertiary structure.  Interestingly, we saw an increase in the amount of 
both FLAG and HIS DmsA that was produced, but unfortunately there was also an 
increase in degradation products evident on the Western blot. 
 Finally, we coexpressed DmsD-Y2 with either DmsA-Y1-FLAG or DmsA-
Y1-HIS in ∆tatC TG1 cells, respectively.  We were able to obtain two clean bands for 
the FLAG epitope with a drastically decreased amount of degradation products; 
however no expression was evident for the HIS construct.  Expression of both DmsD-
Y2 and DmsA-Y1-FLAG resulted in an irreversible association between the two 
proteins through YFP-BiFC and subsequently was able to resist degradation as had 
been seen for the previous cases.   
 
3.4 Purification of the DmsA-DmsD YFP-BiFC complex for crystallography studies 
 In crystallography studies, the use of antibody fragments (e.g. Fab – fragment, 
antigen binding region) (128,129) or the fusion of T4-lysozyme (130) has been 
demonstrated to stabilize the protein complex and allow for the formation of crystals.  
In this same manner, we envision the irreversible nature of YFP-BiFC in helping to 
stabilize the protein complex and in turn aid in the formation of crystal structures 
between the DmsA-DmsD-YFP complexes. 
 Building upon the experimental results seen from the Western blot data in 
Figure 3.1, we engineered DmsD-Y2 to have an N-terminal 8x-HIS epitope, creating 
the plasmid, p8x-HIS-DmsD-Y2.  This N-terminal HIS epitope was previously 
characterized (57) and shown to have no affect on the ability of DmsD to bind to 
ssDmsA.  Additionally, the N-terminal HIS epitope allowed for the purification of 
DmsD from cell lysates using commercially available nickel-nitrilotriacetic acid (Ni- 
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NTA) purification columns.  Coexpression of either ssDmsA-Y1-FLAG/8x-HIS-
DmsD-Y2 or DmsA-Y1-FLAG/8x-HIS-DmsD-Y2 was preformed in ∆tatC TG1 cells 
and a fluorescent signal was detected by both FACS and fluorescence microscopy 
(data not shown).         
 After induction of protein expression, the bacterial cells were centrifuged, 
lysed, and then passed over a Ni-NTA column for metal affinity purification with the 
Figure 3.2 Purification of YFP-BiFC DmsA/DmsD complex.  Flowchart depicting 
process for purifying YFP-BiFC protein complexes beginning with (1) coexpression 
of protein A (ssDmsA-Y1 or DmsA-Y1) with protein D (8x-HIS-DmsD-Y2).  E. coli 
cells are lysed (2), the lysate is applied to a Ni-NTA resin for affinity purification (3).  
After protein samples are collected and concentrated, a native poly- acrylamide gel is  
run for the detection of the protein complex (DmsA/DmsD or ssDmsA/DmsD YFP-
BiFC complexes are shown above). 
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8x-HIS tag attached to DmsD-Y2 (Figure 3.2).  This column was then washed 
extensively to remove any non-specifically bound proteins and subsequently a high 
concentration of imidazole was applied resulting in the elution of the YFP-BiFC 
complex for either ssDmsA or DmsA.  This flow through was collected and 
concentrated resulting in a highly fluorescent solution containing the ssDmsA/DmsD 
or DmsA/DmsD YFP-BiFC complexes. 
 The purified protein complexes stabilized by YFP-BiFC for either 
ssDmsA/DmsD or DmsA/DmsD were separated by native polyacrylamide gel 
electrophoresis (PAGE) and then transferred and detected by Western blotting against 
the C-terminal FLAG tag.  As shown in Figure 3.2, two highly pure complexes were 
detected which are representative of the DmsA/DmsD and ssDmsA/DmsD interactions 
bound by the folded YFP from the YFP-BiFC interaction.  To further validate that we 
had obtained the DmsA/DmsD YFP-BiFC complex, we applied the purified protein to 
a denaturing SDS-PAGE gel and obtained two distinct bands for DmsA-Y1-FLAG 
and 8x-HIS-DmsD-Y2 (Figure 3.3).  Of importance, the folding of the YFP fragments 
does not result in a covalent bond forming, therefore by running a SDS-PAGE gel the  
 
 
 
 
 
 
 
 
 
  
Figure 3.3 SDS-PAGE analysis of the YFP-BiFC DmsA/DmsD complex.  (A) A 4-
20% protein denaturing SDS-PAGE gel was run and stained with Comassie blue for 
visualization of the purified protein.  Purified YFP-BiFC DmsA-Y1/8x-HIS-DmsD-
Y2 was loaded into each well (2µL or 4µL of protein sample in 2x SDS-PAGE 
running buffer).  Two major bands are apparent on the gel, one for DmsA-Y1 
(MW~110kDa) and the second for 8xHIS-DmsD-Y2 (MW~34kDa).  
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two fragments will denature and separate from one another allowing for a spatial 
resolution of the two proteins.  In addition to the two main bands (DmsA and DmsD) 
detected on the SDS-PAGE gel, a third band with a molecular weight of ~ 45kDa was 
also seen.  The identity of this protein is unknown and could either associate with the 
DmsA-DmsD-YFP-BiFC complex or could just be a protein with a high affinity for 
the Ni-NTA purification column.  If necessary, further analysis such as N-terminal 
protein sequencing and mass-spectroscopy would need to be performed to identity this 
protein.  
 Combining the technique of YFP-BiFC assembly with Ni-NTA affinity 
purification we were able to demonstrate that we can purify the two protein 
complexes, ssDmsA/DmsD or DmsA/DmsD which have been trapped in an 
energetically stable configuration through the assembly of YFP.    
 
3.5 Discussion 
 Affinity purification of recombinantly expressed proteins using specially 
designed affinity tags is a well characterized field with extensively validated protocols 
and methodologies.  However, not all recombinantly expressed proteins can tolerate 
the attachment of affinity tags and the stability of over-expressed protein products in 
cells can result in proteolytic cleavage and degradation.   
 Utilizing the irreversible nature of the YFP-BiFC assay, we demonstrate that 
the ssDmsA/DmsD and DmsA/DmsD complexes when held together by YFP are 
stable, they can be purified using Ni-NTA affinity column chromatography 
techniques, and can resist proteolytic degradation.  Additionally, these YFP-BiFC 
complexes are relatively pure and predominantly contain the two interacting protein 
partners with some minimal protein contamination.  Obtaining a relatively pure 
concentrated protein solution and also being able to form a stable protein structure are 
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the essential characteristics for protein X-ray crystallography studies. We are currently 
working with a collaborator, Ailong Ke at Cornell University to obtain the crystal 
structure of the YFP-BiFC DmsA/DmsD complex. 
 In conclusion, we have experimentally validated that the YFP-BiFC assay can 
be combined with Ni-NTA metal affinity chromatography to isolate highly stable and 
contaminate free protein complexes.  We are also the first group to experimentally 
demonstrate that full length DmsA can purified in complex with its chaperone, DmsD.  
 
3.6 Materials and Methods 
3.6.1 Bacterial strains, growth and induction conditions. 
Bacterial strains, growth, and induction conditions used in this study are 
described in Chapter 1.8, unless otherwise mentioned.    
3.6.2 Construction of Plasmids 
 All plasmids used in this study are previously described in Chapter 1.8, with 
the exception of the plasmids listed below in Table 3.1.  For pDmsA-FLAG, an 
internal KpnI cut site was designed before the existing C-terminal FLAG epitope on 
the Y1 fragment.  This extra KpnI cut site allowed removal of the Y1 fragment and 
resulted in a direct DmsA-FLAG fusion.  The pDmsA-Y1-6xHIS plasmid was created 
by PCR amplification of the Y1 fragment using primer MD1768, 5’ – CTC ATG ATC 
GAT TTA ATG GTG ATG GTG ATG GTG GGC CAT GAT ATA GAC GTT GTG G – 3’, 
containing the 6xHIS epitope, and then cloned into KpnI/ClaI cut pDmsA-Y1 
backbone.  To create the pDmsD plasmid, DmsD was PCR amplified and cloned into 
pDmsD-Y2 digested with HindIII/ClaI, resulting in removal of the DmsD-Y2.   
 The p8x-HIS-DmsD-Y2 construct was created with forward PCR primer 
MD2395, 5’ – CTC ATG TCT AGA AAT GCA CCA TCA CCA TCA CCA TCA 
CCA TAC CCA TTT TTC ACA GCA AGA – 3’ and reverse primer MD3124, 5’ – 
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CTC ATG ATG ATT CAT AAC TTT CTG TTT CGG TAC C – 3’, to attach eight 
histidine residues to the N-terminus of DmsD.  This PCR product was digested with 
XbaI and KpnI and replaced wt DmsD in pDmsD-Y2.      
3.6.3 Expression and purification of YFP-BiFC complex. 
 During the initial characterization studies of full length DmsA with C-terminal 
FLAG or HIS epitope tags, expression of the DmsA constructs was performed in 
∆tatC TG1 cells with or without the coexpression of DmsD.  The protein expression 
conditions for the constructs tested were the same as those during YFP-BiFC assays. 
Table 3.1 Plasmids used in this study. 
Plasmid Description Reference 
    pDmsA-FLAG The Y1 fragment was removed from 
pDmsA-Y1 and a C-terminal FLAG 
epitope tag was attached 
This study 
    pDmsA-6xHIS The Y1 fragment was removed from 
pDmsA-Y1 and a C-terminal 6xHIS 
epitope tag was attached 
This study 
    pDmsA-Y1-6xHIS The C-terminal FLAG tag on pDmsA-Y1 
was replaced with a 6xHIS epitope tag  
This study 
    pDmsD The Y2 fragment from pDmsD-Y2 was 
removed 
This study 
    p8x-HIS-DmsD-Y2  8x-HIS tag added to N-terminus of DmsD, 
replacing wt DmsD in pDmsD-Y2.  
This study 
 TG1 ∆tatC cells were co-transformed with either ssDmsA-Y1/8x-HIS-DmsD-
Y2 or DmsA-Y1/8x-HIS-DmsD-Y2 and transformants were recovered as described in 
Chapter 1.8.  Coexpression of the proteins was performed as described in Chapter 1.8, 
however cells recovered after transformation were first pre-cultured for 12 hours at 
RT/200 rpm in 5mL of LB with antibiotics added.  The following day, 2mL of the pre-
culture was added to 400mL of liquid LB with antibiotics and allowed to grow to an 
OD600 ~ 0.5 at 37ºC/200 rpm, induced with 1mM IPTG, and moved to RT/200 rpm for 
8 hours for protein expression. 
 Cells were pelleted at 11,000 x g for 20 minutes at 4ºC.  Supernatant was 
discarded and cell pellets were frozen at -20ºC.  Cell pellets were thawed on ice and 
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the following compounds were added: 5mL of Novagen Bug Buster Master Mix per 
gram of wet cell pellet, the protease inhibitor phenylmethanesulphonyl fluoride 
(PMSF) at a final concentration of 5mM, and 10% (v/v) glycerol.  Cells were then 
resuspended at RT on a 200 rpm rotating platform for 20 minutes and then the cell 
lysate was then spun at 11,000 x g for 20 minutes at 4ºC.  From this point forward, the 
supernatant was kept chilled on ice, passed through a 0.22µm syringe filter to remove 
any whole cells or cellular debris from the soluble fraction.  Imidazole was added to a 
final concentration of 15mM. 
 With the aid of a peristaltic pump, the protein solution was passed over a pre-
equilibrated GE HisTrap HP 1mL column at 1mL/min flow rate.  The column was 
washed with 100mL of binding buffer (500mM NaCl, 20mM Tris-HCl, 15mM 
imidazole, 10% glycerol, pH=7.9), 200mL of wash buffer (same as binding buffer but 
80mM imidazole) and eluted with 25mL of elution buffer (same as binding buffer but 
500mM imiddazole).  The elution fraction was concentrated on 50kDa molecular 
weight cut off (MWCO) VivaSpin20 centrifugal concentrators and then placed into a 
10kDA MWCO dialysis cassette.  Dialysis of the protein was performed overnight at 
4ºC into 1.5L of 25mM HEPES pH = 7.5, 75mM NaCl, 10% glycerol, and 5mM 
dithiothreitol (DTT).   
3.6.4 Verification of epitope characterization studies and protein purification. 
 For the epitope characterization studies, equal amounts of cells (normalized by 
OD600 readings) were lysed with Bug Buster Master Mix and the provided protocol 
from the manufacturer for the isolation of soluble proteins was used.  After mixing the 
soluble proteins in 2x SDS PAGE load dye with beta-mercaptoethanol and incubating 
for 15min at 100ºC, equal volumes of samples were loaded onto a 10% SDS-PAGE 
gel and run for 2 hours at 110 Volts (Figure 3.1).   
 For the purified proteins (ssDmsA-Y1 or DmsA-Y1 with 8x-HIS-DmsD-Y2), 
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after overnight dialysis, two 10µL aliquots of purified protein were removed.  The first 
10µL was added to 2x PAGE loading dye (4mL glycerol, 1mL 0.1% bromophenol 
blue, 2.5mL 0.5M Tris-HCl pH = 6.8), mixed, and applied to a 4-20% PAGE gel, run 
at 100 Volts for 120 minutes resulting in native-non-denatured protein separation 
(Figure 3.2).  The other 10µL of purified protein was mixed with 2x SDS-PAGE 
loading dye (same as 2x PAGE dye but with 0.5mL of beta-mercaptoethanol and 0.4g 
of sodium dodecyl sulfate) and incubated at 100ºC for 15 minutes for denaturing gel 
analysis. Either 2µL or 4µL of sample in loading dye was applied to a 4-20% SDS-
PAGE gel and run for 120 minutes at 100 Volts (Figure 3.3 for just DmsA-Y1/8x-
HIS-DmsD-Y2).  The gel was then stained with BioRad BioSafe Coomassie Blue and 
the image was captured on a BioRad ChemiDoc. 
3.6.5 Western blotting of epitope characterization studies and of purified protein. 
  The SDS-PAGE gel for the epitope characterization studies was transferred 
onto PVDF membranes and probed against the FLAG or HIS epitope tags using 
previously described antibodies for FLAG, while the HIS epitope was detected with a 
primary antibody against HIS conjugated to HRP.  The native protein gel was 
transferred onto PVDF membranes and probed against the FLAG epitope as described 
in Chapter 1.8.     
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CHAPTER 4 
 
UTILIZING YFP-BiFC TO ANALYZE PROTEIN INTERACTIONS BETWEEN A 
DE NOVO DESIGNED THREE HELIX BUNDLE PROTEIN AND THE E. COLI 
TAT PATHWAY 
 
4.1 Introduction 
 The two predominant protein transport pathways in bacteria, the General 
Secretory pathway (Sec) and Signal Recognition Particle (SRP) pathway, allow for the 
transport of proteins into the periplasm in an unfolded or in a co-translational manner, 
respectively (9,131).  In contrast, the Tat pathway is able to export fully folded 
proteins and protein-complexes (e.g. the hitch-hiker mechanism) through the inner 
membrane utilizing the proton motive force that exists between the periplasm and 
cytoplasm (54,78,132,133).  The Tat pathway however does not transport unfolded 
proteins (134,135) due to its protein proofreading and quality control abilities. 
 The Tat translocon (e.g. TatABC) itself acts as a protein proofreading 
mechanism by inhibiting proteins that are incompetent for transport into the periplasm.  
The most basic level of proofreading exists at the recognition of the twin arginine 
residues, whereby the mutation of these residues to twin-lysines allows for the protein 
to interact with and recognition by the Tat machinery components, but it is 
subsequently prevented from being transported into the periplasm (136,137).  The Tat 
pathway chaperone DmsD serves as a quality control mechanism by stabilizing the 
folding of DmsA and by preventing premature export of the substrate before cofactor 
insertion (57,138).  These two methods provide the Tat pathway with a degree of 
specificity and selectivity as to the types of proteins that can be transported into the 
periplasm. 
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 From a biotechnological application perspective, the ability to have an in vivo 
proofreading and quality control mechanism would provide for an internal checkpoint 
for the production of high value therapeutics without the need to worry about the 
folding state of the protein of interest.  Understanding how the Tat pathway is able to 
recognize and prevent export of unfolded or export-incompetent proteins has been 
investigated (90,134,139), and a selection tool utilizing the export of the antibiotic 
resistance conferring protein beta-lactamase has been designed to identify proteins that 
are Tat export competent from a de novo designed library (114); however a direct in 
vivo protein reporter that allows interrogation of the Tat pathway components with the 
de novo designed protein has yet to been developed. 
 Here we demonstrate the utility of the YFP-BiFC assay and its ability to report 
on the folding status of a de novo designed three helix bundle protein as it interacts 
with either the TatC or DmsD.   
  
4.2 Description of α3A – α3B de novo designed proteins 
 Within the last decade, especially after the sequencing of the human genome, 
the number of fully sequenced genomes across a broad range of organisms has 
continuously increased.  Additionally, the protein crystallography community has 
expanded the number of solved protein crystal structures with advancements in high 
throughput automated methods for the production, purification, and screening of 
proteins of interest for potential drug therapies (140,141).  The information obtained 
from both the genomic DNA sequences and protein structures has allowed for the 
development of computer simulations that can begin to predict the function of 
unknown proteins (142).            
 Knowledge gained from the identification and characterization of native 
proteins has provided the field of de novo protein design with a framework for the 
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necessary conditions that allow for proteins to attain a stable folded structure and 
perform a certain function (143,144).  The initial starting point for de novo protein 
design is done with bioinformatic analysis and in silico modeling of small protein 
sequences (consisting of 30-70 amino acid residues) that are patterned after naturally 
occurring motifs such as zinc fingers (145-148), coiled coils (149), or other small 
protein domains (150,151).  Typically these proteins have a secondary structure 
consisting of alpha helices that can subsequently interact with one another to form 
bundles. 
 For our proof of concept experiments we wished to use the YFP-BiFC assay as 
a reporter on the folding state of a de novo designed protein as it interacts with either 
TatC or DmsD.  Therefore we chose a de novo three helix bundle protein (3,4) that   
had a clear directed evolutionary lineage, was well characterized, and could be easily 
manipulated for the YFP-BiFC assay.  The three helix bundle family of proteins we 
selected named, α3A through α3D are shown below (Table 4.1) and their respective 
amino acid sequence alignment is shown in Figure 4.1.   
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Characteristics of α3 helix bundle proteins.  Proteins α3A to α3D, 
described below, were evolved through bioinformatic and computational analysis 
from the parental 2 helix bundle Coil-Ser protein as described in Bryson et. al. 1998 
(4).  
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 The α3 helix bundle family of proteins originates from a de novo designed two 
helix bundle protein, Coil-Ser (152) that was created with a repeating periodic 
structure and was intended to form a homodimer that would stabilize the two bundles.  
When analyzed in solution, the peptide existed as a combination of monomer, dimers, 
and trimers while its X-ray structure showed an anti-parallel three-stranded coiled coil 
(153) demonstrating that the anticipated de novo designed structure was invalid and 
needed to be refined.  Through directed evolution techniques based off of the 
determined X-ray structure, α3A was created whereby hairpin loops were engineered 
to stabilize the bundles, but the protein still remained molten globular and was still 
aggregation prone upon analysis.              
Figure 4.1 Description of de novo designed three helix bundle proteins α3A-α3D.  
(A) Protein alignment of α3A-α3D using ClustalW in DNASTAR LaserGene software 
package, with α3A as base for protein evolution.  Symbol (.) is a conserved residue, 
while (~) is a amino acid insertion.  (B) NMR structure of the three helix bundle 
protein α3D as described by Walsh et. al. 1999 (3) (PDB ID 2a3d) displayed without 
or with internal hydrophobic amino acid residues (left and right images, respectively). 
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 Further protein evolution generated α3B, which was now a monomeric protein 
due to the addition of specific helix-capping motifs to the loop regions of the bundles, 
however this protein still was classified as having a molten globular structure due to 
the lack of hydrophobic residues at the center of the protein.  Through the combined 
efforts of redesigning the electrostatic interactions between the helices and utilizing in 
silico modeling algorithms to repack and generate a hydrophobic core, the α3C 
evolved variant was created.  When analyzed, α3C had an ordered monomeric three 
helix bundle structure and behaved like a native protein when denatured and tested for 
the lack of binding to 8-anilino-naphthalene sulfonic acid (ANS) which is a 
fluorescence dye that can bind to molten globular proteins (4).    
 Finally, the α3D protein was evolved from α3C by expanding the amino acid 
diversity to include 19 out of the 20 natural amino acids and when characterized, α3D 
retained a monomeric and ordered structure.  Furthermore the α3D protein was stable 
enough for nuclear magnetic resonance (NMR) solution structure solving (Figure 4.1 
B) and demonstrated the characteristics that were anticipated from the de novo design 
parameters (3).  Having this family of three helix bundle proteins, which have been 
engineered for their stability, their ability to exist as monomers in solution and their 
native like resemblance of natural proteins, we were now able to utilize the YFP-BiFC 
assay to determine how dynamic interactions between folded and unfolded proteins 
occurs between Tat pathway components.   
 
 4.2 Interactions between three helix bundle proteins and DmsD monitored 
with YFP-BiFC 
 The first native Tat pathway interaction we studied and validated as a proof of 
concept with YFP-BiFC was the association between ssDmsA-Y1 and DmsD-Y2.  
Utilizing the affinity of the chaperone DmsD for ssDmsA, we created a tripartite 
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fusion protein with an N-terminal ssDmsA signal peptide, one of the four α3 helix 
proteins, and the C-terminal Y1 fragment (e.g. ssDmsA-α3A-Y1) and coexpressed 
these with DmsD-Y2 in wt TG1 cells for YFP-BiFC analysis (Figure 4.2 A).      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 YFP-BiFC analyses of interactions between ssDmsA-α3-Y1 and 
DmsD-Y2.  (A) Coexpression of ssDmsA-Y1, ssDmsA-α3A-Y1 through ssDmsA-
α3D, with DmsD-Y2 in wt TG1 cells.  Unfused Y1, was coexpressed with DmsD-Y2 
and served as the negative control.  Median cell fluorescence was obtained via FACS 
with 3 replicate experiments (n = 3) and was normalized to the ssDmsA-Y1/DmsD-Y2 
signal.  (B) Western blot analysis of periplasmic (panel 1 and 2) and cytoplasmic 
(panel 3 and 4) fractions from wt TG1 cells.  All samples were fused to Y1 C-
terminally, α3A-α3D had N-terminal ssDmsA fusions, while (-) was just Y1 and were 
coexpressed with DmsD-Y2.  Panels 1 and 3 were detected using a anti-FLAG 
antibody against the C-terminal FLAG epitope on the Y1 fragment.  Panel 2 is probed 
against GroEL, a cytoplasmic fractionation marker, with anti-GroEL.  Panel 4 was 
probed with anti-GFP which detects the Y2 fragment fused to DmsD.     
 74 
 When the YFP-BiFC signal was normalized to the ssDmsA-Y1/DmsD-Y2 
interaction, a greater than 2 fold signal was observed for the protein chimeras with 
α3A and α3B and slowly began to decrease for α3C, while the α3D signal was near that 
seen for the ssDmsA interaction.  This decrease in fluorescence can be attributed to the 
flexibility and folding state of the α3 helix bundle that is fused between ssDmsA and 
Y1.  We hypothesize the relative steric hindrances for molten globular structures (e.g. 
α3A) are much lower than that of an ordered protein (e.g. α3D), which can increase the 
probability that the two YFP fragments will interact with one another and this is 
reflected with an increase in detectable YFP-BiFC signal.   
 After seeing this decrease in fluorescence levels as the stability of the α3 helix 
protein increased, we wished to validate that the decrease in signal was not due to a 
lower expression level of either the ssDmsA chimeric protein or the chaperone DmsD.  
The relative levels of expressed protein by visual inspection were similar when we 
fractionated the cells and Western blotted to detect either the ssDmsA chimeric protein 
or the chaperone DmsD in the cytoplasmic fraction (Figure 4.2 B, panel 3 or panel 4, 
respectively).  Additionally, we looked for the transport of the ssDmsA-Y1 or 
ssDmsA- α3A/α3B/α3C/α3D-Y1 chimeric proteins into the periplasm (Figure 4.2 B, 
panel 1) and we were able to detect the active transport of all the Tat competent 
substrates (ssDmsA-Y1, ssDmsA-α3B/α3C/α3D-Y1), while the unfused Y1 protein and 
the ssDmsA-α3A-Y1 were not present.  In the case of the molten globular and 
aggregation prone α3A protein, the chimeric protein can interact with the soluble 
cytoplasmic DmsD chaperone and generate an intense YFP-BiFC signal; however 
periplasmic export of this protein is prevented.  A similar increase in YFP-BiFC signal 
was seen when Tat machinery components were eliminated (e.g. ∆tatC TG1 cells) and 
ssDmsA-Y1/DmsD-Y2 were coexpressed (Figure 1.7 A). 
 The YFP-BiFC assay demonstrates that protein interactions between a Tat 
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pathway chaperone and a family of de novo designed proteins can be monitored and 
that the fluorescent signal intensity is an in vivo reporter for the folding status of the 
protein of interest between the ssDmsA and Y1.  Furthermore, Western blot evidence 
demonstrates that the quality control and proofreading mechanisms of the Tat pathway 
are functional and prevent export of Tat incompetent substrates.  This is the first 
demonstration that the YFP-BiFC assay can detect interactions between either 
globular unfolded proteins or structured proteins with DmsD in a functional Tat 
pathway.   
 
4.3 Interactions between three helix bundle proteins and TatC monitored with YFP-
BiFC 
 After validating that the YFP-BiFC assay can report on and discriminate 
between the interactions of differentially folded proteins (e.g. the α3 helix bundle 
family) with the Tat pathway chaperone DmsD, we wished to determine if YFP-BiFC 
assay could be applied to monitor differentially folded protein interactions with the 
Tat translocase component, TatC.  Utilizing the previously designed TatC-Y2 
chimeric protein we coexpressed the ssDmsA-α3A/α3B/α3C/α3D-Y1 in ∆tatABCE TG1 
cells and detected a fluorescent YFP-BiFC signal which was normalized to the 
ssDmsA-Y1/TatC-Y2 control (Figure 4.3).   
 As previously seen for the chaperone DmsD case, the trend for the decrease in 
the fluorescent YFP-BiFC signal occurs as the α3 helix bundle family moves from the 
molten globular structure to an ordered one (e.g. α3A to α3D) when it interacts with the 
TatC-Y2 chimeric protein.  The low YFP-BiFC signal for the α3A chimeric protein 
can be attributed to the aggregation prone nature of this protein which can prevent it 
from interacting with TatC.  As for α3B, an increase in YFP-BiFC fluorescence can be 
attributed to the flexibility of the chimeric protein whereby the steric hindrances are  
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minimized allowing for a greater number of YFP fragments to associate with one 
another.  The α3C chimeric protein YFP-BiFC signal resembled that of ssDmsA-Y1 
while the α3D chimeric proteins show a marked decrease in YFP-BiFC fluorescence 
that can be attributed the steric restrictions that the helix bundle imposes on the Y1 
fragment and its ability to interact with TatC.  Overall, we are able to demonstrate that 
the YFP-BiFC assay can be used to detect the interactions between differentially 
folded types of helical bundle proteins as they interact with a Tat translocon 
component.      
 
4.4 Discussion 
 The coupling of de novo designed three helix bundle proteins of varying folded 
conformational states with the YFP-BiFC assay has allowed us to monitor the in vivo 
protein interactions between the α3 chimeras and DmsD or TatC.  By using a tripartite 
Figure 4.3 Interaction between TatC and ssDmsA-α3A-α3D-Y1 detected by YFP-
BiFC.  Proteins ssDmsA-Y1, ssDmsA-α3A-Y1 through ssDmsA-α3D-Y1 were 
coexpressed with TatC-Y2 in TG1 ∆tatABCE cells.  Unfused Y1 was coexpressed 
with TatC-Y2 was used as a negative control.  Median fluorescence values were 
obtained via FACS and the data was normalized to the ssDmsA-Y1/TatC-Y2 signal.  
The values reported are the average of 3 replicated measurements (n = 3).    
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fusion protein (e.g. ssDmsA-α3A-Y1) coexpressed with DmsD-Y2, we were able to 
detect a fluorescent YFP-BiFC signal regardless of the folded state of the α3 protein.  
However when we analyzed the ability of the Tat pathway to export these chimeric 
fusions by Western blotting, we were able to see the quality control and proofreading 
mechanism was fully functional and prevented the export of the ssDmsA-α3A-Y1 
fusion due to its molten globular and aggregation prone nature.   
 Additionally, we were able to detect interactions using YFP-BiFC between the 
same chimeric α3 fusions and TatC-Y2 demonstrating that even unfolded, molten 
globular proteins can interact with the Tat translocon machinery, albeit at lower YFP-
BiFC signal intensities.  Although these experiments with TatC-Y2 were performed in 
∆tatABCE TG1 cells, future experiments will be conducted in ∆tatC TG1 cells to 
determine how the YFP-BiFC signal intensity changes when other Tat components 
present.           
 Finally, we have demonstrated for the first time that the folding status of a de 
novo designed three helix bundle protein can be monitored via YFP-BiFC as it 
interacts with either a Tat chaperone or a Tat translocon machinery component.  This 
fluorescent assay can be potentially applied to screen libraries of other de novo 
designed helix bundles (154) for the isolation and identification of other types of 
proteins that can interact with and be transported by the Tat pathway. 
 
4.5 Materials and Methods 
4.5.1 Bacterial strains, growth and induction conditions. 
 Bacterial strains, growth, and induction conditions used in this study are 
described in Chapter 1.8, unless otherwise mentioned.   
4.5.2 Construction of plasmids. 
 All plasmids used in this study are previously described in Chapter 1.8, with 
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the exception of the plasmids listed below in Table 4.2.  Plasmid pssDmsA-NdeI-
SpeI-Y1 was designed by PCR amplification of ssDmsA with forward primer 
MD1007 5’ – CTC ATG GCA TGC CTG CAG TAT GAA AAC GAA AAT CCC TGA 
TGC G – 3’ and  reverse primer MD 3051 5’ – CTC ATG GGT ACC GCA CTA GTG 
TCG ACC ATA TGG GCG CTA TCG ACA GCG TGC GCA ATC CGA – 3’.  This 
PCR product was digested with HindIII and KpnI and inserted into pssDmsA-Y1 
replacing the ssDmsA sequence.  Plasmids containing the genes encoding for proteins 
α3A-α3D were provided as a gift of Dr. William F. DeGrado and were digested with 
NdeI and SpeI and cloned into similarly digested pssDmsA-NdeI-SpeI-Y1.      
Table 4.2 Plasmids used in this study. 
Plasmid Description Reference
    pssDmsA-NdeI-SpeI-Y1 NdeI and SpeI cutsites were inserted after 
the ssDmsA signal peptide and before the 
KpnI cutsite.     
This work 
    pssDmsA-α3A-Y1 
 
The α3A gene was inserted into the NdeI 
and SpeI sites of pssDmsA-NdeI-SpeI-Y1  
This work 
    pssDmsA-α3B-Y1 The α3B gene was inserted into the NdeI 
and SpeI sites of pssDmsA-NdeI-SpeI-Y1 
This work 
    pssDmsA-α3C-Y1 The α3C gene was inserted into the NdeI 
and SpeI sites of pssDmsA-NdeI-SpeI-Y1 
This work 
    pssDmsA-α3D-Y1 The α3D gene was inserted into the NdeI 
and SpeI sites of pssDmsA-NdeI-SpeI-Y1 
This work 
4.5.3 Fluorescence measurements 
Cell fluorescence measurements were obtained via FACS as previously 
described in Chapter 1.8. 
4.5.4 Cellular fractionation and Western blotting. 
 Cellular fractionation and Western blotting were performed as previously 
described in Chapter 1.8.  
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CHAPTER 5 
 
EXPANDING YFP-BiFC FOR FRET ANALYSIS OF PROTEIN INTERACTIONS 
ALONG THE TAT PATHWAY 
 
5.1 Introduction 
 In this post genomic era, identifying the DNA coding for proteins has become 
trivial, however understanding the function of the protein of interest (POI) and 
subsequently mapping the interactions between the POI and other proteins that are 
expressed has been delegated to field of proteomics.  The ability to identify protein-
protein interactions can be preformed using in vitro methodologies such as affinity 
column chromatography whereby the POI is captured by an affinity tag to the column 
and then a cellular lysate is flowed over the column resulting in the association of 
proteins to the POI (57).  After subsequent washing steps and elution of the POI-
protein complex, the resulting proteins can be identified through N-terminal protein 
sequencing using Edman degradation (155) and/or mass spectroscopy analysis (156).  
This in vitro method however can result in a high number of false positive proteins 
due to non-specific interactions between proteins on the chromatography column. 
 The development of identification technologies that combine in vivo with 
subsequent in vitro analysis such as formaldehyde cross-linking with immuno-
precipitation (157,158) begin to identify specific complexes, but again are limited due 
to the potential cross-linking effects by incorporating non-specific proteins.  Yeast two 
hybrid (159) and bacterial two hybrid (160) systems are purely in vivo methods for the 
detection of protein-protein interactions whereby the interaction of two proteins causes 
transcriptional activation of a reporter gene and subsequent production of a reporter 
protein (e.g. beta-galactosidase or GFP).  This in vivo method does not succumb to 
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non-specific protein interactions as the previously described methods do, however the 
assay gives an indirect report of the interaction of the two proteins since it is 
dependent on the transcription of a reporter protein. 
 Two purely in vivo methods, Förster/fluorescence resonance energy transfer 
(FRET) and bimolecular fluorescence complementation (BiFC), have been developed 
for the detection of protein interactions.  Both of these methods utilize a fluorescent 
protein (e.g. CFP) or protein fragments (e.g. YFP) which are fused genetically to the 
POI and subsequent interactions can be monitored both temporally and spatially.  Here 
we demonstrate that interactions between multiple Tat pathway proteins can be 
monitored using a CFP–YFP-BiFC–FRET assay.       
 
5.2 The CFP–YFP-BiFC–FRET premise 
 We have previously demonstrated that YFP-BiFC can monitor protein-protein 
interactions in the E. coli Tat pathway; however this assay is limited in scope because 
it is only able to report on the interactions between two specific proteins (e.g. DmsA 
and DmsD).  Since numerous proteins are involved in the Tat translocon, we wished to 
apply the technique of FRET to determine how these protein complexes interact with 
one another.  FRET is a biophysical process whereby non-radiative energy is 
transferred from a donor molecule to an acceptor molecule as long as the two 
molecules are located within a distance of 10 nano-meters (nm) and their transition 
dipole moments are aligned (161,162).   
 The two most commonly used GFP spectral variants for FRET analysis are 
cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) (163).  When 
CFP (ex. 434nm/em. 477nm) and YFP (ex. 513/em. 527nm) are farther than 10nm 
from one another, FRET will not occur; however when the distance is less than 10nm, 
the emission energy from CFP will excite YFP and an increase in the relative YFP to  
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CFP signal will occur demonstrating that FRET is occurring (Figure 5.1 A).  
 Utilizing the YFP-BiFC assay that we have developed to monitor protein 
interactions in vivo in the E. coli Tat pathway, we wished to additionally complex CFP 
Figure 5.1 Applying YFP-BiFC-FRET to monitor Tat-substrate-CFP with Tat-
machinery-BiFC interactions.  (A) When CFP or YFP are expressed, excitation of 
the protein fluorophore (434nm or 513nm, respectively) results in fluorescence 
(477nm or 527nm, respectively).  However if the CFP and YFP are within 10nm of 
one another, fluorescence resonance energy transfer (FRET) can occur, whereby the 
CFP is excited at 434nm, emission occurs at 477nm but the non-radiative energy is 
absorbed by YFP, resulting in excitation of the fluorophore, and emission at 527nm.  
(B) Schematic diagram of how TatB-Y1 and TatC-Y2 when coexpressed reconstitute 
fluorescent YFP by BiFC.  When ssDmsA-CFP is then expressed, the ssDmsA signal 
peptide directs the CFP to the TatBC complex, bringing the CFP into proximity and a 
subsequent YFP-BiFC-FRET signal can be generated.   
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with another Tat pathway component to determine if a FRET signal could be detected 
between the protein complexes.  Published experimental evidence has demonstrated 
that two E. coli Tat pathway proteins, NarJ and NarG, can be detected using CFP-YFP 
FRET (164) and the premise of CFP–YFP-BiFC–FRET has been demonstrated in 
eukaryotic cells (165,166).  From these two lines of evidence, we are confident that a 
FRET signal can be generated in vivo in the Tat pathway.   
 
5.3 Targeting interactions between Tat pathway machinery and protein substrates 
for FRET interrogation  
 From the YFP-BiFC analysis of the Tat pathway, many of the components 
used to detect interactions between proteins have been developed and described in 
Chapter 1.  Full length CFP was fused C-terminally to either ssDmsA or TatC, 
generating two additional protein chimeras, ssDmsA-CFP and TatC-CFP, which allow 
for FRET analysis within the Tat pathway.  For a FRET signal to occur the level of 
donor protein (CFP) has to be expressed at a lower level than the acceptor protein 
(YFP) because with a higher ratio of acceptor to donor protein the probability of 
energy transfer to the acceptor protein is increased and results in a higher signal to 
noise ration.  We therefore placed the two CFP protein chimeras into a low copy 
arabinose inducible vector pBAD33 while the YFP-BiFC assay plasmids were left 
unaltered.   
 Two Tat pathway interactions that gave an appreciable YFP-BiFC signal were 
TatB-Y1/TatC-Y2 and ssDmsA-Y1/DmsD-Y2, so we added a third plasmid for FRET 
analysis to both of these systems resulting in TatB-Y1/TatC-Y2/ssDmsA-CFP and 
ssDmsA-Y1/DmsD-Y2/TatC-CFP (Figure 5.1 B and Figure 5.2, respectively).  Since 
FRET is dependent on the relative signal ratio between the YFP to CFP, our negative 
control was CFP expressed from pBAD33 with both of the YFP-BiFC components 
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(e.g. TatB-Y1/TatC-Y2/CFP).  CFP expression would result in a distribution of 
fluorescent protein evenly throughout the cytoplasm of E. coli and would not localize 
to the cell poles nor interact with the Tat pathway proteins.             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 Preliminary experiments demonstrating YFP-BiFC FRET  
 The CFP–YFP-BiFC–FRET plasmids and the respective negative control CFP 
plasmid were transformed into ∆tatC TG1 cells.  After induction of protein 
expression, a FRET signal was determined by taking the ratio of the YFP to CFP 
fluorescent signal intensity for both the FRET interacting plasmid combinations and 
for the FRET negative control.  This ratio was then plotted against the relative 
fluorescence of the acceptor fluorophore (YFP) and a FRET signal could be 
determined from this data.  
Figure 5.2 Applying YFP-BiFC-FRET to monitor TatC-CFP with YFP-BiFC 
ssDmsA-Y1/DmsD-Y2.  (A) Coexpression of TatC-CFP (C-terminal fusion) in TG1 
∆tatC cells with YFP-BiFC ssDmsA-Y1/DmsD-Y2.  The ssDmsA-Y1/DmsD-Y2 
complex is targeted to TatC-CFP, therefore allowing for the interaction of ssDmsA 
with TatC-CFP, bringing YFP into proximity with CFP permitting FRET.     
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 We were able to detect a FRET signal for the plasmid combinations ssDmsA-
Y1/DmsD-Y2/TatC-CFP that had an apparent intensity that was 1.1–1.3 times greater 
than that for negative control (Figure 5.3).    The lack of a FRET signal for the TatB-  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Y1/TatC-Y2/ssDmsA-CFP could be the result of numerous factors, a) ∆tatC TG1 cells 
actively exporting ssDmsA-CFP into the periplasm, b) the ratio between the acceptor 
(YFP) to donor (CFP) protein is incorrect and c) the distance between the two protein 
pairs is beyond the maximum 10nm, preventing FRET from occurring.  Future 
experiments on optimizing the FRET conditions and addressing the factors described 
for the lack of a FRET signal will potentially clarify these results.   
 We have demonstrated for the first time that an YFP-BiFC-FRET signal can be 
detected in the E. coli Tat pathway.  By using a combinatorial approach, proteins 
associated with the Tat pathway were expressed in vivo that first interacted to generate 
Figure 5.3 YFP-BiFC-FRET between TatC-CFP and ssDmsA-Y1/DmsD-Y2.  
Coexpression of either pBAD33Cm-TatC-CFP/ssDmsA-Y1/DmsD-Y2 (▲) or 
pBAD33Cm-CFP/ssDmsA-Y1/DmsD-Y2 (■) in ∆tatC TG1 cells.  The FRET signal 
ratio observed for the pBAD33Cm-TatC-CFP/ssDmsA-Y1/DmsD-Y2 versus the 
pBAD33Cm-CFP/ssDmsA-Y1/DmsD-Y2 complex is plotted against the fluorescence 
units (AU) of YFP in each sample.    
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a YFP-BiFC signal (e.g. ssDmsA-Y1/DmsD-Y2) and then interacted with the Tat 
translocon protein TatC-CFP.  The cells were then lysed and in vitro experiments were 
performed to demonstrate that a FRET signal could be detected between the YFP-
BiFC complex and the Tat-CFP translocon illustrating that the fluorescent proteins are 
within the Föster radius that allows for FRET to occur. 
  
5.5 Discussion 
 With the development of two fluorescent in vivo techniques, BiFC and FRET, 
protein-protein interactions can be both spatially and temporally monitored in their 
native environments.  We have demonstrated that YFP-BiFC can be applied to 
monitor protein interactions throughout the entirety of E. coli Tat pathway; however 
YFP-BiFC is limited in its ability to only report on two protein interactions while Tat 
transport involves numerous proteins that act in complex.  Applying FRET alleviates 
this problem of YFP-BiFC by the addition of a second fluorescent protein (CFP) 
which in turn allows for the determination of the spatial organization of the proteins 
and also maintains the in vivo detection abilities of these assays.   
 We have demonstrated for the first time that a CFP–YFP-BiFC–FRET assay 
can be developed for the combinatorial in vivo and in vitro monitoring of protein 
complexes in the E. coli Tat pathway.  Using two previously validated YFP-BiFC 
proteins (e.g. ssDmsA-Y1/DmsD-Y2) and a FRET protein partner (e.g. C-terminally 
tagged TatC-CFP) we were able to detect a FRET signal that was 1.1-1.3 fold over 
background.  This evidence demonstrates that a combination of in vivo fluorescent 
proteins can be used to detect interactions between numerous proteins and that the 
distance between the Tat translocon machinery component TatC and the ssDmsA-
Y1/DmsD-Y2 complex is within the Föster distance to allow for a FRET signal to be 
generated.       
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 To further investigate how Tat machinery components assemble and interact, 
the application of a CFP-BiFC–YFP-BiFC–FRET assay has been envisioned.  
Evidence from the YFP-BiFC characterization of the Tat pathway demonstrated that 
numerous machinery proteins interact with one another (e.g. TatB-Y1/TatC-Y2) and 
with substrates directed for export (e.g. ssDmsA-Y1/TatC-Y2).  By applying two 
different fluorescent BiFC assays, we hypothesize that we can capture two protein 
interactions with CFP-BiFC (e.g. TatB-C1/TatC-C2) and two protein interactions with 
YFP-BiFC (e.g. ssDmsA-Y1/DmsD-Y2) and then have the two BiFC complexes 
interact to generate a FRET signal.  Optimization of the expression levels of the BiFC 
complexes will need to be determined along with the induction conditions for protein 
production because YFP and CFP BiFC complexes can cross associate (e.g. ssDmsA-
Y1/TatC-C2) and generate aberrant complexes that would limit the detectable FRET 
signal. 
 Overall, we have demonstrated for the first time that a CFP–YFP-BiFC–FRET 
signal can be detected in vivo in the Tat pathway of E. coli and that this assay can be 
expanded into a CFP-BiFC–YFP-BiFC–FRET technique that can monitor how the Tat 
pathway functions as a complex of proteins.    
 
5.6 Materials and Methods 
5.6.1 Bacterial strains, growth and induction conditions. 
 Bacterial strains and growth conditions used in this study are described in 
Chapter 1.8.  Induction of protein expression was done in a two step manner.  After 
cells were grown to an OD600~0.5 at 37ºC/200 rpm, 1mM IPTG was added and cells 
were transferred to RT/200 rpm and allowed to grow for 6 hours for expression of 
ssDmsA-Y1/DmsD-Y2 for YFP-BiFC.  After 6 hours, 0.2% L-arabinose (final 
concentration) was added for induction of Tat-CFP expression from pBAD33Cm 
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TatC-CFP and cells were grown for another 10 hours at RT/200 rpm.  
5.6.2 Construction of plasmids. 
 All plasmids used in this study are previously described in Chapter 1.8, with 
the exception of the plasmids listed below in Table 5.1.  Plasmid pCyan (pBAD33Cm-
CFP) encoding Cyan fluorescent protein (CFP) was provided as a gift from Dr. Patrick 
S. Daugherty (58).  PCR amplification of CFP was preformed using forward primer 
MD2984 5’ – CTC ATG GGT ACC GAA TTC GCG TAG CAT TGC GAC CTC 
TAA AGG TGA AGA ATT ATT CGG CGG – 3’ and reverse primer MD2987 5’ - 
CTC ATG ATC GAT CTT TAT TAT TTG TAC AAT TCA TCC ATA CCA TGG 
GTA ATA CCA GCA GCA – 3’.  The PCR product was digested with KpnI and ClaI 
and inserted into similarly digested pssDmsA-Y1 or pTatC-Y2 TetR, whereby the Y1 
or Y2 fragments were replaced with CFP, respectively; generating pssDmsA-CFP and 
pTatC-CFP TetR.  The TatC-CFP construct was then PCR amplified using forward 
primer MD3054 5’ – CTC ATG GAG CTC AGG AGG AAT TCA CCA TGT CTG 
TAG AAG ATA CTC AAC CGC TTA TCA CGC – 3’ and reverse primer MD3041 
5’ – CTC ATG GTC GAC TTA TTA TTT GTA CAA TTC ATC CAT ACC ATG 
GGT AAT ACC AGC AGC AGT – 3’.  This PCR product was then digested with 
SacI and SalI and cloned into similarly digested pBAD33Cm creating the final 
plasmid pBAD33Cm-TatC-CFP.         
5.6.3 FRET measurements and Data analysis 
 Cell density between samples pBAD33Cm-CFP/pssDmsA-Y1/pDmsD-Y2 and 
pBAD33Cm-TatC-CFP/pssDmsA-Y1/pDmsD-Y2 was normalized by OD600 readings.  
Cells (4-5mL) were centrifuged for 1 minute at 16,000 x g, 4ºC and subsequently 
treated with 400µL of Bug Buster Master Mix for 20 minutes at RT/200 rpm resulting 
in cell lysis.  Cell lysate was then centrifuged for 20 minutes, 16,000 x g, at 4ºC and 
the supernatant (containing the soluble and membrane fractions) was collected.   
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Table 5.1 Plasmids used in this study. 
Plasmid Description Reference
    pBAD33Cm-CFP pBAD33Cm expressing CFP from 
Nguyen et. al.     
(58) 
    pssDmsA-CFP 
 
The gene for CFP was inserted C-
terminal to pssDmsA-Y1 replacing the 
Y1 fragment . 
This work 
    pTatC-CFP TetR The gene for CFP was inserted C-
terminal to pTatC-Y2 TetR replacing 
the Y2 fragment. 
This work 
    pBAD33Cm-ssDmsA-CFP ssDmsA-CFP from pssDmsA-CFP 
was cloned into pBAD33Cm 
This work 
    pBAD33Cm-TatC-CFP TatC-CFP from pTatC-CFP TetR 
cloned into pBAD33Cm 
This work 
200µL of lysate was applied to the first column of a Costar flat bottom, high binding, 
and solid black 96 well plate.  100µL of lysate was serially diluted in 100µL of 1x 
PBS, resulting in a range of concentrations from 100 to 10-11. 
 The 96 well plate was then placed into a Biotek Synergy HT plate reader and 
fluorescence measurements were determined using the following filter set 
combinations: CFP fluorescence (excitation 400/30, emission 460/40), YFP 
fluorescence (excitation 485/20, emission 528/20), and FRET (excitation 400/30, 
emission 528/20).  After fluorescence data was acquired, the ratio between the FRET 
signal and the CFP signal was taken for dilutions 100 to 10-5.  This value is the FRET 
signal ratio (Figure 5.3) and it is plotted against the YFP signal obtained for each of 
the samples.              
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